

Renal and ureteric stones: assessment and management

Methodology

NICE guideline

Methodology chapter

July 2018

Consultation

*Developed by the National Guideline Centre,
hosted by the Royal College of Physicians*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© National Institute for Health and Care Excellence, 2018

Contents

1	Development of the guideline	5
1.1	What is a NICE guideline?.....	5
1.2	Remit.....	5
1.3	Who developed this guideline?.....	6
1.3.1	What this guideline covers	6
1.3.2	What this guideline does not cover.....	7
1.3.3	Relationships between the guideline and other NICE guidance	7
2	Methods	8
2.1	Developing the review questions and outcomes	8
2.2	Searching for evidence.....	13
2.2.1	Clinical and health economics literature searches.....	13
2.3	Identifying and analysing evidence of effectiveness	14
2.3.1	Inclusion and exclusion criteria	14
2.3.2	Type of studies.....	15
2.3.3	Methods of combining clinical studies	15
2.3.4	Appraising the quality of evidence by outcomes.....	18
2.3.5	Assessing clinical importance	25
2.3.6	Clinical evidence statements.....	25
2.4	Identifying and analysing evidence of cost effectiveness	25
2.4.1	Literature review	26
2.4.2	Undertaking new health economic analysis.....	27
2.4.3	Cost-effectiveness criteria	28
2.4.4	In the absence of health economic evidence.....	29
2.5	Developing recommendations	29
2.5.1	Research recommendations	30
2.5.2	Validation process.....	30
2.5.3	Updating the guideline	30
2.5.4	Disclaimer	30
2.5.5	Funding.....	30
3	Additional information: Expert testimony on paediatric care in renal and ureteric stones	31
4	Acronyms and abbreviations	32
5	Glossary	33
5.1	Guideline-specific terms	33
5.2	General and methodological terms	37

1 Development of the guideline

1.1 What is a NICE guideline?

NICE guidelines are recommendations for the care of individuals in specific clinical conditions or circumstances within the NHS – from prevention and self-care through primary and secondary care to more specialised services. These may also include elements of social care or public health measures. We base our guidelines on the best available research evidence, with the aim of improving the quality of healthcare. We use predetermined and systematic methods to identify and evaluate the evidence relating to specific review questions.

NICE guidelines can:

- provide recommendations for the treatment and care of people by health professionals
- be used to develop standards to assess the clinical practice of individual health professionals
- be used in the education and training of health professionals
- help patients to make informed decisions
- improve communication between patient and health professional.

While guidelines assist the practice of healthcare professionals, they do not replace their knowledge and skills.

We produce our guidelines using the following steps:

- A guideline topic is referred to NICE from NHS England.
- Stakeholders register an interest in the guideline and are consulted throughout the development process.
- The scope is prepared by the National Guideline Centre (NGC).
- The NGC establishes a guideline committee.
- A draft guideline is produced after the group assesses the available evidence and makes recommendations.
- There is a consultation on the draft guideline.
- The final guideline is produced.

The guideline is made up of a collection of documents including this Methods report and a number of evidence reports covering each of the review questions included in the guideline. These can all be downloaded from NICE at www.nice.org.uk.

NICE also publishes a summary of the recommendation in this guideline, known as ‘the NICE guideline’.

NICE Pathways brings together all connected NICE guidance.

1.2 Remit

NICE received the remit for this guideline from NHS England. NICE commissioned the NGC to produce the guideline.

The remit for this guideline is: Renal stones: Assessment and management of renal stones

To prepare a clinical guideline on the assessment and management of renal and ureteric stones.

1.3 Who developed this guideline?

A multidisciplinary guideline committee comprising health professionals and researchers as well as lay members developed this guideline (see the list of guideline committee members and the acknowledgements).

The National Institute for Health and Care Excellence (NICE) funds the National Guideline Centre (NGC) and thus supported the development of this guideline. The committee was convened by the NGC and chaired by Andrew Dickinson in accordance with guidance from NICE.

The group met approximately every 6 weeks during the development of the guideline. At the start of the guideline development process all committee members declared interests including consultancies, fee-paid work, shareholdings, fellowships and support from the healthcare industry. At all subsequent committee meetings, members declared arising conflicts of interest.

Members were either required to withdraw completely or for part of the discussion if their declared interest made it appropriate. The details of declared interests and the actions taken are shown in the declaration of interest register for this guideline published on the NICE website.

Staff from the NGC provided methodological support and guidance for the development process. The team working on the guideline included a project manager, systematic reviewers (research fellows), health economists and information specialists. They undertook systematic searches of the literature, appraised the evidence, conducted meta-analysis and cost-effectiveness analysis where appropriate and drafted the guideline in collaboration with the committee.

1.3.1 What this guideline covers

Groups that are covered

- Adults, children and young people with renal or ureteric stones (kidney and ureteric stones)
- Subgroups of people identified as needing specific consideration include:
 - pregnant women
 - people who are HIV positive and having treatment with protease inhibitors.

Key areas that are covered

- Imaging for diagnosing and assessing renal and ureteric stones (for example, CT, ultrasound).
- Pharmacological management of symptomatic renal and ureteric stones (for example, non-steroidal anti-inflammatory drugs, opioids and alpha-blockers).
- Surgical interventions for symptomatic renal and ureteric stones (for example, for upper and lower pole renal stones, upper and lower ureteric stones).
- Managing asymptomatic renal and ureteric stones.
- Metabolic investigation (for example, blood tests, urinalysis and stone analysis).
- Follow-up management in people who have or have had renal or ureteric stones, including:
 - imaging
 - pharmacological treatment (for example, thiazide diuretics)
 - dietary interventions
 - lifestyle interventions (for example, weight loss and exercise).

1 For further details please refer to the scope for this guideline (published on the NICE
2 website) and the review questions in section 2.1.

3 **1.3.2 What this guideline does not cover**

4 **Areas that are not covered**

- 5 • Bladder stones.
- 6 • Open surgery for renal and ureteric stones.

7 **1.3.3 Relationships between the guideline and other NICE guidance**

8 **Related NICE interventional procedures guidance:**

- 9 • Laparoscopic nephrolithotomy and pyelolithotomy (2007) NICE interventional procedure
10 guidance IPG212
- 11 • Minimally invasive percutaneous nephrolitholapaxy medium (MIP-M) for removing kidney
12 stones (2018) Medtech innovation briefing [MIB138]


13
14

2 Methods

This report sets out in detail the methods used to review the evidence and to develop the recommendations that are presented in each of the evidence reviews for this guideline. This guidance was developed in accordance with the methods outlined in the NICE guidelines manual, 2014 version.²

Sections 2.1 to 2.3 describe the process used to identify and review clinical evidence (summarised in Figure 1), sections 2.2 and 2.4 describe the process used to identify and review the health economic evidence, and section 2.5 describes the process used to develop recommendations.

Figure 1: Step-by-step process of review of evidence in the guideline



2.1 Developing the review questions and outcomes

Review questions were developed using a PICO framework (population, intervention, comparison and outcome) for intervention reviews; using a framework of population, index tests, reference standard and target condition for reviews of diagnostic test accuracy; using population, presence or absence of factors under investigation (for example prognostic factors) and outcomes for prognostic reviews; and using a framework of population, setting and context for qualitative reviews.

This use of a framework guided the literature searching process, critical appraisal and synthesis of evidence, and facilitated the development of recommendations by the guideline committee. The review questions were drafted by the NGC technical team and refined and

1 validated by the committee. The questions were based on the key clinical areas identified in
2 the scope.

3 A total of 11 review questions were identified.

4 Full literature searches, critical appraisals and evidence reviews were completed for all the
5 specified review questions.

6 **Table 1: Review questions**

Evidence report	Type of review	Review questions	Outcomes
1	Diagnostic	In people with suspected (or under investigation for) renal and ureteric stones, how accurate is ultrasound, plain abdominal radiograph or MRI to identify whether a renal or ureteric stone is present, as indicated by the reference standard, non-contrast CT?	Diagnostic accuracy of: <ul style="list-style-type: none"> • Specificity • Sensitivity
2	Intervention	What is the clinical and cost-effectiveness of drugs in managing acute pain in people with symptomatic renal or ureteric stones?	Critical outcomes <ul style="list-style-type: none"> • Quality of life • Pain intensity: visual analogue scale, verbal ratings, descriptive scales, time to pain relief, need to rescue medication • Major adverse events: GI haemorrhage, acute kidney injury, and respiratory depression, mortality, cardiac event. • Minor adverse events: GI disturbance without bleeding, vomiting and nausea, constipation, diarrhoea, pain, dizziness, sleepiness, urinary retention Important outcomes: <ul style="list-style-type: none"> • Length of stay • Use of healthcare services
3	Intervention	Is medical expulsive therapy clinically and cost-effective in managing people with ureteric stones?	Critical outcomes: <ul style="list-style-type: none"> • Time to stone-passage • Stone passage rate • Use of healthcare services/hospitalization • Quality of life • Adverse events: hypotension, and dizzy spells, falls, floppy iris, retrograde ejaculation, headaches, flushing

Evidence report	Type of review	Review questions	Outcomes
			<p>Important outcomes:</p> <ul style="list-style-type: none"> Pain intensity (visual analogue scale, verbal ratings, descriptive scales, time to pain relief, need to rescue medication) Analgesic use
4	Intervention	What is the most clinically and cost-effective length of time to manage people (adults, children and young people) with symptomatic or asymptomatic renal or ureteric stones conservatively before intervention (early versus delayed intervention)?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> Spontaneous stone passing Surgical intervention required
5	Intervention	Is inserting a stent clinically and cost-effective before surgical treatment in people with renal or ureteric stones?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> Stone-free rate (including residual fragment) Recurrence rate Use of healthcare services (length of stay, readmission, retreatment or ancillary procedure) Kidney function Quality of life Major adverse events (infective complications [sepsis, obstructive pyelonephritis], ureteric injury [ureteral damage, ureteral perforation, ureteral stricture], mortality) Minor adverse events (infective complications [UTI, fever, infection], ureteric injury [extravasation, submucosal dissection], haemorrhage [any bleeding, transfusion]) Failure to treat (inaccessible stone, stone not seen/reached) <p>Important outcomes:</p> <ul style="list-style-type: none"> Pain intensity (visual analogue scale)
6	Intervention	What are the most clinically and cost-effective surgical treatment options for people with renal or ureteric stones?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> Stone-free rate (including residual fragment) Recurrence rate

Evidence report	Type of review	Review questions	Outcomes
			<ul style="list-style-type: none"> • Use of healthcare services (length of stay, readmission, retreatment or ancillary procedure) • Kidney function • Quality of life • Major adverse events (infective complications [sepsis, obstructive pyelonephritis], ureteric injury [ureteral damage, ureteral perforation, ureteral stricture], mortality) • Minor adverse events (infective complications [UTI, fever, infection], ureteric injury [extravasation, submucosal dissection], haemorrhage [any bleeding, transfusion]) • Failed technology (inaccessible stone, stone not seen/reached) <p>Important outcomes:</p> <ul style="list-style-type: none"> • Pain intensity (visual analogue scale)
7	Intervention	Is inserting a stent clinically and cost-effective after surgical treatment in people with renal or ureteric stones?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • Stone-free rate (including residual fragment) • Recurrence rate • Use of healthcare services (length of stay, readmission, retreatment or ancillary procedure) • Kidney function • Quality of life • Major adverse events (infective complications [sepsis, obstructive pyelonephritis], ureteric injury [ureteral damage, ureteral perforation, ureteral stricture], mortality) • Minor adverse events (infective complications [UTI, fever, infection], ureteric injury)

Evidence report	Type of review	Review questions	Outcomes
			<p>[extravasation, submucosal dissection], haemorrhage [any bleeding, transfusion])</p> <ul style="list-style-type: none"> • Failure to treat (inaccessible stone, stone not seen/reached) <p>Important outcomes:</p> <ul style="list-style-type: none"> • Pain intensity (visual analogue scale)
8	Diagnostic test and treat	In people with renal or ureteric stones, what is the clinical and cost effectiveness of stone analysis, blood test and urine test compared to no test, when each is followed by the appropriate treatment for renal and ureteric stones, in order to improve patient outcomes?	<p>Clinical effectiveness outcomes:</p> <ul style="list-style-type: none"> • Stone recurrence • Stone interventions (surgery/admission /MET) • Metabolic abnormalities found • Quality of life • Adverse events related to test • Adverse events related to treatment • Number of people receiving treatment
9	Intervention	In people who have or have had renal or ureteric stone, what is the optimum frequency of imaging?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • Stone free • Change in stone size • Stone recurrence • Quality of life • Unplanned admissions • Intervention
10	Intervention	What is the clinical and cost-effectiveness of dietary interventions to reduce the risk of future stones in people who have had renal stones?	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • New stone formation/incidence of stones/recurrence rate • Change in metabolic test (urine calcium, urine pH, urine oxalate, urine sodium) • Change in stone risk score • Use of healthcare services/retreatment rate • Quality of life • Adverse events <p>Important outcomes:</p> <ul style="list-style-type: none"> • Compliance/adherence • Kidney function
11	Intervention	What is the most clinically-effective and cost-effective non-surgical management for preventing the	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • Recurrence rate

Evidence report	Type of review	Review questions	Outcomes
		recurrence of future renal and ureteric stones?	<ul style="list-style-type: none"> Stone episodes/stone interventions Use of healthcare services Quality of life Major Adverse events (if admission to hospital) Minor adverse events (no admission to hospital) Important outcomes: <ul style="list-style-type: none"> Kidney function Pain intensity (visual analogue scale)

1 2.2 Searching for evidence

2 2.2.1 Clinical and health economics literature searches

3 Systematic literature searches were undertaken to identify all published clinical and health
 4 economic evidence relevant to the review questions. Searches were undertaken according to
 5 the parameters stipulated within the NICE guidelines manual 2014 (see
 6 [https://www.nice.org.uk/media/default/about/what-we-do/our-programmes/developing-nice-](https://www.nice.org.uk/media/default/about/what-we-do/our-programmes/developing-nice-guidelines-the-manual.pdf/)
 7 [guidelines-the-manual.pdf/](https://www.nice.org.uk/media/default/about/what-we-do/our-programmes/developing-nice-guidelines-the-manual.pdf/)). Databases were searched using relevant medical subject
 8 headings, free-text terms and study-type filters where appropriate. Where possible, searches
 9 were restricted to papers published in English. Studies published in languages other than
 10 English were not reviewed. For specific criteria, including dates, see Appendix B of the
 11 relevant review. If new evidence, falling outside of the timeframe for the guideline searches,
 12 is identified, for example in consultation comments received from stakeholders, the impact on
 13 the guideline will be considered, and any further action agreed between NGC and NICE staff
 14 with a quality assurance role.

15 Prior to running, search strategies were quality assured using a variety of approaches.
 16 Medline search strategies were checked by a second information specialist before being run.
 17 Searches were cross-checked with reference lists of highly relevant papers, searches in
 18 other systematic reviews were analysed, and committee members were requested to
 19 highlight additional studies.

20 During the scoping stage, a search was conducted for guidelines and reports on the websites
 21 including:

- 22 • Guidelines International Network database (www.g-i-n.net)
- 23 • National Guideline Clearing House (www.guideline.gov)
- 24 • NHS Evidence Search (www.evidence.nhs.uk)
- 25 • DUETs (<http://www.library.nhs.uk/duets/>)
- 26 • BMJ Clinical Evidence (<http://clinicalevidence.bmj.com/>)
- 27 • Trip Database (<http://www.tripdatabase.com/>)
- 28 • Cochrane Database of Systematic Reviews (CDSR) (<http://www.thecochranelibrary.com/>)
- 29 • Urology Care Foundation (<http://www.urologyhealth.org/research>)
- 30 • American Urological Association (<https://www.auanet.org/>)
- 31 • British Association of Urological Surgeons (<https://www.baus.org.uk/default.aspx>)
- 32 • Canadian Urological Association (<https://www.cua.org/>)

- 1 • Urological Society of Australia and New Zealand (www.usanz.org.au/)
- 2 Searching for unpublished literature was not undertaken. The NGC and NICE do not have
3 access to drug manufacturers' unpublished clinical trial results, so the clinical evidence
4 considered by the committee for pharmaceutical interventions may be different from that
5 considered by the MHRA and European Medicines Agency for the purposes of licensing and
6 safety regulation.
- 7 Detailed search strategies can be found as an appendix to each evidence review.

8 **2.3 Identifying and analysing evidence of effectiveness**

9 Research fellows conducted the tasks listed below, which are described in further detail in
10 the rest of this section:

- 11 • Identified potentially relevant studies for each review question from the relevant search
12 results by reviewing titles and abstracts. Full papers were then obtained.
- 13 • Reviewed full papers against prespecified inclusion and exclusion criteria to identify
14 studies that addressed the review question in the appropriate population, and reported on
15 outcomes of interest (review protocols are included in an appendix to each of the
16 evidence reports).
- 17 • Critically appraised relevant studies using the appropriate study design checklist as
18 specified in the NICE guidelines manual.²
- 19 • Extracted key information about interventional study methods and results using 'Evibase',
20 NGC's purpose-built software. Evibase produces summary evidence tables, including
21 critical appraisal ratings. Key information about non-interventional study methods and
22 results was manually extracted onto standard evidence tables and critically appraised
23 separately (evidence tables are included in an appendix to each of the evidence reports).
- 24 • Generated summaries of the evidence by outcome. Outcome data were combined,
25 analysed and reported according to study design:
- 26 ○ Randomised data were meta-analysed where appropriate and reported in GRADE
27 profile tables.
 - 28 ○ Data from non-randomised studies were meta-analysed if appropriate. Where evidence
29 was not meta-analysed, because key confounders were not adjusted for or there were
30 differences in baseline, results from single studies were presented separately.
 - 31 ○ Diagnostic data studies were meta-analysed where appropriate. Where evidence was
32 not meta-analysed, because of insufficient data, results from single studies were
33 presented separately.
- 34 • A sample of a minimum of 10% of the abstract lists of the first 3 sifts by new reviewers
35 and those for complex review questions (for example, prognostic reviews) were double-
36 sifted by a senior research fellow and any discrepancies were rectified. All of the evidence
37 reviews were quality assured by a senior research fellow. This included checking:
- 38 ○ papers were included or excluded appropriately
 - 39 ○ a sample of the data extractions
 - 40 ○ correct methods were used to synthesise data
 - 41 ○ a sample of the risk of bias assessments.

42 **2.3.1 Inclusion and exclusion criteria**

43 The inclusion and exclusion of studies was based on the criteria defined in the review
44 protocols, which can be found in an appendix to each of the evidence reports. Excluded
45 studies (with the reasons for their exclusion) are listed in another appendix to each of the
46 evidence reports. The committee was consulted about any uncertainty regarding inclusion or
47 exclusion.

- 1 The key population inclusion criterion was:
- 2 • Adults (16 and over) and children who have or have had renal or ureteric stones, or
 - 3 who have symptoms of renal or ureteric stones.

4 The key population exclusion criterion was:

- 5
- 6 • People with bladder stones
- 7 • People undergoing open surgery for renal and ureteric stones

8 Literature reviews, posters, letters, editorials, comment articles, unpublished studies,
9 conference abstracts and studies not in English were excluded.

10 **2.3.2 Type of studies**

11 Randomised trials, non-randomised intervention studies, and other observational studies
12 (including diagnostic studies) were included in the evidence reviews as appropriate.

13 For most intervention reviews in this guideline, parallel randomised controlled trials (RCTs)
14 were included because they are considered the most robust type of study design that can
15 produce an unbiased estimate of the intervention effects. If non-randomised intervention
16 studies were considered appropriate for inclusion (for example, where no randomised
17 evidence was available for the paediatric population) the committee stated a priori in the
18 protocol that either certain identified variables must be equivalent at baseline or else the
19 analysis had to adjust for any baseline differences. In this guideline the committee did not
20 exclude studies if these variables were not considered. This is because of the general
21 paucity of evidence available for the paediatric population. However, the limitations of
22 uncontrolled data were captured in the study quality assessment and highlighted during
23 committee discussions of the relevant evidence. Please refer to the review protocols in each
24 evidence report for full details on the study design of studies selected for each review
25 question.

26 For diagnostic review questions, diagnostic RCTs (also known as test and treat studies),
27 cross-sectional studies and retrospective studies were included. Case-control studies were
28 not included.

29 Where data from non-randomised studies were included, the results for each outcome were
30 presented separately for each study or meta-analysed if appropriate.

31 **2.3.3 Methods of combining clinical studies**

32 **2.3.3.1 Data synthesis for intervention reviews**

33 Where possible, meta-analyses were conducted using Cochrane Review Manager
34 (RevMan5)⁸ software to combine the data given in all studies for each of the outcomes of
35 interest for the review question.

36 All analyses were stratified for age (under 16 years and 16 years or over), which meant that
37 different studies with predominant age-groups in different age strata were not combined and
38 analysed together. For some questions additional stratification was used, and this is
39 documented in the individual review question protocols in each evidence report. When
40 additional strata were used this led to substrata (for example, using 2 stratification criteria
41 leads to 4 substrata, using 3 stratification criteria leads to 9 substrata) which were analysed
42 separately.

12.3.3.1.1 *Analysis of different types of data*

2 **Dichotomous outcomes**

3 Fixed-effects (Mantel–Haenszel) techniques (using an inverse variance method for pooling)
4 were used to calculate risk ratios (relative risk, RR) for the binary outcomes, which included:

- 5 • stone-free state
- 6 • stone passage
- 7 • time to stone passage
- 8 • retreatment
- 9 • recurrence
- 10 • ancillary procedures
- 11 • use of healthcare services
- 12 • adverse events
- 13 • analgesic use
- 14 • failed technology

15 The absolute risk difference was also calculated using GRADEpro¹ software, using the
16 median event rate in the control arm of the pooled results.

17 For binary variables where there were zero events in either arm or a less than 1% event rate,
18 Peto odds ratios, rather than risk ratios, were calculated. Peto odds ratios are more
19 appropriate for data with a low number of events.

20 Where sufficient information was provided, rate ratios were calculated for outcomes such as
21 recurrence rate, where the time to the event occurring was important for decision-making.

22 **Continuous outcomes**

23 Continuous outcomes were analysed using an inverse variance method for pooling weighted
24 mean differences. These outcomes included:

- 25 • quality of life (QoL)
- 26 • length of stay in hospital
- 27 • pain
- 28 • kidney function.

29 Where the studies within a single meta-analysis had different scales of measurement,
30 standardised mean differences were used (providing all studies reported either change from
31 baseline or final values rather than a mixture of both); each different measure in each study
32 was ‘normalised’ to the standard deviation value pooled between the intervention and
33 comparator groups in that same study.

34 The means and standard deviations of continuous outcomes are required for meta-analysis.
35 However, in cases where standard deviations were not reported, the standard error was
36 calculated if the p values or 95% confidence intervals (95% CI) were reported, and meta-
37 analysis was undertaken with the mean and standard error using the generic inverse
38 variance method in Cochrane Review Manager (RevMan5⁸ software. Where p values were
39 reported as ‘less than’, a conservative approach was undertaken. For example, if a p value
40 was reported as ‘p≤0.001’, the calculations for standard deviations were based on a p value
41 of 0.001. If these statistical measures were not available then the methods described in
42 section 16.1.3 of the Cochrane Handbook (version 5.1.0, updated March 2011) were applied.

12.3.3.1.2 **Generic inverse variance**

2 If a study reported only the summary statistic and 95% CI the generic-inverse variance
3 method was used to enter data into RevMan5.⁸ If the control event rate was reported this
4 was used to generate the absolute risk difference in GRADEpro.¹ If multivariate analysis was
5 used to derive the summary statistic but no adjusted control event rate was reported no
6 absolute risk difference was calculated.

72.3.3.1.3 **Heterogeneity**

8 Statistical heterogeneity was assessed for each meta-analysis estimate by considering the
9 chi-squared test for significance at $p < 0.1$ or an I-squared (I^2) inconsistency statistic (with an I-
10 squared value of more than 50% indicating significant heterogeneity) as well as the
11 distribution of effects. Where significant heterogeneity was present, predefined subgrouping
12 of studies was carried out as specified a priori in the review protocols, and included:

- 13 • Pregnant women
- 14 • People with HIV and having treatment with protease inhibitors
- 15 • Location of the stone (distal, mid or proximal ureteric; upper or lower pole renal)
- 16 • People with asymptomatic or symptomatic stones

17 If the subgroup analysis resolved heterogeneity within all of the derived subgroups, then
18 each of the derived subgroups were adopted as separate units for analysis (providing at least
19 1 study remained in each subgroup. Assessments of potential differences in effect between
20 subgroups were based on the chi-squared tests for heterogeneity statistics between
21 subgroups. Any subgroup differences were interpreted with caution as separating the groups
22 breaks the study randomisation and as such is subject to uncontrolled confounding.

23 If all predefined strategies of subgrouping were unable to explain statistical heterogeneity
24 within each derived subgroup, then a random effects (DerSimonian and Laird) model was
25 employed to the entire group of studies in the meta-analysis. A random-effects model
26 assumes a distribution of populations, rather than a single population. This leads to a
27 widening of the confidence interval around the overall estimate, thus providing a more
28 realistic interpretation of the true distribution of effects across more than 1 population. If,
29 however, the committee considered the heterogeneity was so large that meta-analysis was
30 inappropriate, then the results were described narratively.

312.3.3.1.4 **Complex analysis**

32 Network meta-analysis was considered for the comparison of surgical intervention
33 treatments, but was not pursued because of insufficient data available for the relevant
34 outcomes.

35 **2.3.3.2 Data synthesis for diagnostic test accuracy reviews**

362.3.3.2.1 **Diagnostic RCTs**

37 Diagnostic RCTs (sometimes referred to as test and treat trials) are a randomised
38 comparison of 2 diagnostic tests, with study outcomes being clinically important
39 consequences of the diagnosis (patient-related outcome measures similar to those in
40 intervention trials, such as mortality). Patients are randomised to receive test A or test B,
41 followed by identical therapeutic interventions based on the results of the test (so someone
42 with a positive result would receive the same treatment regardless of whether they were
43 diagnosed by test A or test B). Downstream patient outcomes are then compared between
44 the 2 groups. As treatment is the same in both arms of the trial, any differences in patient
45 outcomes will reflect the accuracy of the tests in correctly establishing who does and does
46 not have the condition. Data were synthesised using the same methods for intervention
47 reviews (see section 2.3.3.1.1 above).

12.3.3.2.2 **Diagnostic accuracy studies**

2 Diagnostic test accuracy measures used in the analysis were: area under the receiver
3 operating characteristics (ROC) curve (AUC), and, sensitivity and specificity. The threshold
4 of a diagnostic test is defined as the value at which the test can best differentiate between
5 those with and without the target condition. In practice this varies amongst studies. If a test
6 has a high sensitivity then very few people with the condition will be missed (few false
7 negatives). For example, a test with a sensitivity of 97% will only miss 3% of people with the
8 condition. Conversely, if a test has a high specificity then few people without the condition
9 would be incorrectly diagnosed (few false positives). For example, a test with a specificity of
10 97% will only incorrectly diagnose 3% of people who do not have the condition as positive.
11 For this guideline, sensitivity was considered more important than specificity due to the
12 consequences of a missed stone (false negative result). Coupled forest plots of sensitivity
13 and specificity with their 95% CIs across studies (at various thresholds) were produced for
14 each test, using RevMan5.⁸ In order to do this, 2×2 tables (the number of true positives, false
15 positives, true negatives and false negatives) were directly taken from the study if given, or
16 else were derived from raw data or calculated from the set of test accuracy statistics.

17 Diagnostic meta-analysis was conducted where appropriate, that is, when 3 or more studies
18 were available per test, and the data was sufficient. Test accuracy for the studies was pooled
19 using the bivariate method for the direct estimation of summary sensitivity and specificity
20 using a random-effects approach in WinBUGS software.¹¹ The advantage of this approach is
21 that it produces summary estimates of sensitivity and specificity that account for the
22 correlation between the 2 statistics. Other advantages of this method have been described
23 elsewhere.^{7, 9, 10} The bivariate method uses logistic regression on the true positives, true
24 negatives, false positives and false negatives reported in the studies. Overall sensitivity and
25 specificity and confidence regions were plotted (using methods outlined by Novielli 2010.⁵)
26 Pooled sensitivity and specificity and their 95% CIs were reported in the clinical evidence
27 summary tables. If values could not be pooled, then the individual sensitivity values and their
28 coupled specificity were presented in the clinical evidence summary.

29 If appropriate, to allow comparison between tests, summary ROC curves were generated for
30 each diagnostic test from the pairs of sensitivity and specificity calculated from the 2×2
31 tables, selecting 1 threshold per study. A ROC plot shows true positive rate (sensitivity) as a
32 function of false positive rate (1 minus specificity). Data were entered into RevMan5⁸ and
33 ROC curves were fitted using the Moses-Littenberg approach. In order to compare diagnostic
34 tests, 2 or more tests were plotted on the same graph. The performance of the different
35 diagnostic tests was then assessed by examining the summary ROC curves visually: the test
36 that had a curve lying closest to the upper left corner (100% sensitivity and 100% specificity)
37 was interpreted as the best test.

38 Heterogeneity or inconsistency amongst studies was visually inspected in the forest plots
39 and pooled diagnostic meta-analysis plots.

40 **2.3.4 Appraising the quality of evidence by outcomes**

41 **2.3.4.1 Intervention reviews**

42 The evidence for outcomes from the included RCTs and, where appropriate, non-randomised
43 intervention studies, were evaluated and presented using an adaptation of the 'Grading of
44 Recommendations Assessment, Development and Evaluation (GRADE) toolbox' developed
45 by the international GRADE working group (<http://www.gradeworkinggroup.org/>). The
46 software (GRADEpro¹) developed by the GRADE working group was used to assess the
47 quality of each outcome, taking into account individual study quality and the meta-analysis
48 results.

1 Each outcome was first examined for each of the quality elements listed and defined in Table
2 2.

3 **Table 2: Description of quality elements in GRADE for intervention studies**

Quality element	Description
Risk of bias	Limitations in the study design and implementation may bias the estimates of the treatment effect. Major limitations in studies decrease the confidence in the estimate of the effect. Examples of such limitations are selection bias (often due to poor allocation concealment), performance and detection bias (often due to a lack of blinding of the patient, healthcare professional or assessor) and attrition bias (due to missing data causing systematic bias in the analysis).
Indirectness	Indirectness refers to differences in study population, intervention, comparator and outcomes between the available evidence and the review question.
Inconsistency	Inconsistency refers to an unexplained heterogeneity of effect estimates between studies in the same meta-analysis.
Imprecision	Results are imprecise when studies include relatively few patients and few events (or highly variable measures) and thus have wide confidence intervals around the estimate of the effect relative to clinically important thresholds. 95% confidence intervals denote the possible range of locations of the true population effect at a 95% probability, and so wide confidence intervals may denote a result that is consistent with conflicting interpretations (for example a result may be consistent with both clinical benefit AND clinical harm) and thus be imprecise.
Publication bias	Publication bias is a systematic underestimate or overestimate of the underlying beneficial or harmful effect due to the selective publication of studies. A closely related phenomenon is where some papers fail to report an outcome that is inconclusive, thus leading to an overestimate of the effectiveness of that outcome.
Other issues	Sometimes randomisation may not adequately lead to group equivalence of confounders, and if so this may lead to bias, which should be taken into account. Potential conflicts of interest, often caused by excessive pharmaceutical company involvement in the publication of a study, should also be noted.

4 Details of how the 4 main quality elements (risk of bias, indirectness, inconsistency and
5 imprecision) were appraised for each outcome are given below. Publication or other bias was
6 only taken into consideration in the quality assessment if it was apparent.

72.3.4.1.1 *Risk of bias*

8 The main domains of bias for RCTs are listed in Table 3. Each outcome had its risk of bias
9 assessed within each study first. For each study, if there were no risks of bias in any domain,
10 the risk of bias was given a rating of 0. If there was risk of bias in just 1 domain, the risk of
11 bias was given a 'serious' rating of -1, but if there was risk of bias in 2 or more domains the
12 risk of bias was given a 'very serious' rating of -2. A weighted average score was then
13 calculated across all studies contributing to the outcome, by taking into account the weighting
14 of studies according to study precision. For example if the most precise studies tended to
15 each have a score of -1 for that outcome, the overall score for that outcome would tend
16 towards -1.

17 **Table 3: Principle domains of bias in randomised controlled trials**

Limitation	Explanation
Selection bias (sequence generation and allocation concealment)	If those enrolling patients are aware of the group to which the next enrolled patient will be allocated, either because of a non-random sequence that is predictable, or because a truly random sequence was not concealed from the researcher, this may translate into systematic selection bias. This may occur if the researcher chooses not to recruit a participant into that specific group because of:

Limitation	Explanation
	<ul style="list-style-type: none"> • knowledge of that participant's likely prognostic characteristics, and • a desire for one group to do better than the other.
Performance and detection bias (lack of blinding of patients and healthcare professionals)	<p>Patients, caregivers, those adjudicating or recording outcomes, and data analysts should not be aware of the arm to which patients are allocated. Knowledge of the group can influence:</p> <ul style="list-style-type: none"> • the experience of the placebo effect • performance in outcome measures • the level of care and attention received, and • the methods of measurement or analysis <p>all of which can contribute to systematic bias.</p>
Attrition bias	<p>Attrition bias results from an unaccounted for loss of data beyond a certain level (a differential of 10% between groups). Loss of data can occur when participants are compulsorily withdrawn from a group by the researchers (for example, when a per-protocol approach is used) or when participants do not attend assessment sessions. If the missing data are likely to be different from the data of those remaining in the groups, and there is a differential rate of such missing data from groups, systematic attrition bias may result.</p>
Selective outcome reporting	<p>Reporting of some outcomes and not others on the basis of the results can also lead to bias, as this may distort the overall impression of efficacy.</p>
Other limitations	<p>For example:</p> <ul style="list-style-type: none"> • Stopping early for benefit observed in randomised trials, in particular in the absence of adequate stopping rules. • Use of unvalidated patient-reported outcome measures. • Lack of washout periods to avoid carry-over effects in crossover trials. • Recruitment bias in cluster-randomised trials.

1 The assessment of risk of bias differs for non-randomised intervention studies, as they are
2 inherently at high risk of selection bias. For this reason, GRADE requires that non-
3 randomised evidence is initially downgraded on the basis of study design, starting with a
4 rating of -2. This accounts for selection bias and so non-randomised intervention studies are
5 not downgraded any further on that domain. Non-randomised evidence was assessed
6 against the remaining domains used for RCTs in Table 3, and downgraded further as
7 appropriate.

82.3.4.1.2 Indirectness

9 Indirectness refers to the extent to which the populations, interventions, comparisons and
10 outcome measures are dissimilar to those defined in the inclusion criteria for the reviews.
11 Indirectness is important when these differences are expected to contribute to a difference in
12 effect size, or may affect the balance of harms and benefits considered for an intervention.
13 As for the risk of bias, each outcome had its indirectness assessed within each study first.
14 For each study, if there were no sources of indirectness, indirectness was given a rating of 0.
15 If there was indirectness in just 1 source (for example in terms of population), indirectness
16 was given a 'serious' rating of -1, but if there was indirectness in 2 or more sources (for
17 example, in terms of population and treatment) the indirectness was given a 'very serious'
18 rating of -2. A weighted average score was then calculated across all studies contributing to
19 the outcome by taking into account study precision. For example, if the most precise studies
20 tended to have an indirectness score of -1 each for that outcome, the overall score for that
21 outcome would tend towards -1.

222.3.4.1.3 Inconsistency

23 Inconsistency refers to an unexplained heterogeneity of results for an outcome across
24 different studies. When estimates of the treatment effect across studies differ widely, this
25 suggests true differences in the underlying treatment effect, which may be due to differences

1 in populations, settings or doses. When heterogeneity existed within an outcome (chi-
2 squared $p < 0.1$, or $I^2 > 50\%$), but no plausible explanation could be found, the quality of
3 evidence for that outcome was downgraded. Inconsistency for that outcome was given a
4 'serious' score of -1 if the I^2 was 50–74%, and a 'very serious' score of -2 if the I^2 was 75%
5 or more.

6 If inconsistency could be explained based on prespecified subgroup analysis (that is, each
7 subgroup had an $I^2 < 50\%$), the committee took this into account and considered whether to
8 make separate recommendations on new outcomes based on the subgroups defined by the
9 assumed explanatory factors. In such a situation the quality of evidence was not downgraded
10 for those emergent outcomes.

11 Since the inconsistency score was based on the meta-analysis results, the score
12 represented the whole outcome and so weighted averaging across studies was not
13 necessary.

142.3.4.1.4 **Imprecision**

15 The criteria applied for imprecision were based on the 95% CIs for the pooled estimate of
16 effect, and the minimal important differences (MID) for the outcome. The MIDs are the
17 threshold for appreciable benefits and harms, separated by a zone either side of the line of
18 no effect where there is assumed to be no clinically important effect. If either end of the 95%
19 CI of the overall estimate of effect crossed 1 of the MID lines, imprecision was regarded as
20 serious and a 'serious' score of -1 was given. This was because the overall result, as
21 represented by the span of the confidence interval, was consistent with 2 interpretations as
22 defined by the MID (for example, both no clinically important effect and clinical benefit were
23 possible interpretations). If both MID lines were crossed by either or both ends of the 95% CI
24 then imprecision was regarded as very serious and a 'very serious' score of -2 was given.
25 This was because the overall result was consistent with all 3 interpretations defined by the
26 MID (no clinically important effect, clinical benefit and clinical harm). This is illustrated in
27 Figure 2. As for inconsistency, since the imprecision score was based on the meta-analysis
28 results, the score represented the whole outcome and so weighted averaging across studies
29 was not necessary.

30 The position of the MID lines is ideally determined by values reported in the literature.
31 'Anchor-based' methods aim to establish clinically meaningful changes in a continuous
32 outcome variable by relating or 'anchoring' them to patient-centred measures of clinical
33 effectiveness that could be regarded as gold standards with a high level of face validity. For
34 example, a MID for an outcome could be defined by the minimum amount of change in that
35 outcome necessary to make patients feel their quality of life had 'significantly improved'.
36 MIDs in the literature may also be based on expert clinician or consensus opinion concerning
37 the minimum amount of change in a variable deemed to affect quality of life or health. For
38 binary variables, any MIDs reported in the literature will inevitably be based on expert
39 consensus, as such MIDs relate to all-or-nothing population effects rather than measurable
40 effects on an individual, and so are not amenable to patient-centred 'anchor' methods.

41 In the absence of values identified in the literature, the alternative approach to deciding on
42 MID levels is the 'default' method, as follows:


- 43 • For categorical outcomes the MIDs were taken to be RRs or Peto ORs of 0.8 and 1.25.
44 For 'positive' outcomes such as 'patient satisfaction', the RR or Peto OR of 0.8 is taken as
45 the line denoting the boundary between no clinically important effect and a clinically
46 significant harm, whilst the RR or Peto OR of 1.25 is taken as the line denoting the
47 boundary between no clinically important effect and a clinically significant benefit. For
48 'negative' outcomes such as 'bleeding', the opposite occurs, so the RR or Peto OR of 0.8
49 is taken as the line denoting the boundary between no clinically important effect and a
50 clinically significant benefit, whilst the RR or Peto OR of 1.25 is taken as the line denoting
51 the boundary between no clinically important effect and a clinically significant harm.

- For continuous outcome variables the MID was taken as half the median baseline standard deviation of that variable, across all studies in the meta-analysis. Hence the MID denoting the minimum clinically significant benefit was positive for a 'positive' outcome (for example, a quality of life measure where a higher score denotes better health), and negative for a 'negative' outcome (for example, a visual analogue scale [VAS] pain score). Clinically significant harms will be the converse of these. If baseline values are unavailable, then half the median comparator group standard deviation of that variable will be taken as the MID.
- If standardised mean differences have been used, then the MID will be set at the absolute value of +0.5. This follows because standardised mean differences are mean differences normalised to the pooled standard deviation of the 2 groups, and are thus effectively expressed in units of 'numbers of standard deviations'. The 0.5 MID value in this context therefore indicates half a standard deviation, the same definition of MID as used for non-standardised mean differences.

The default MID value was subject to amendment after discussion with the committee. If the committee decided that the MID level should be altered, after consideration of absolute as well as relative effects, this was allowed, provided that any such decision was not influenced by any bias towards making stronger or weaker recommendations for specific outcomes.

For this guideline, no appropriate MID values for continuous or dichotomous outcomes were found in the literature, and so the default method was adopted.

Figure 2: Illustration of precise and imprecise outcomes based on the 95% CI of dichotomous outcomes in a forest plot (Note that all 3 results would be pooled estimates, and would not, in practice, be placed on the same forest plot)



222.3.4.1.5 Overall grading of the quality of clinical evidence

Once an outcome had been appraised for the main quality elements, as above, an overall quality grade was calculated for that outcome. The scores (0, -1 or -2) from each of the main quality elements were summed to give a score that could be anything from 0 (the best possible) to -8 (the worst possible). However scores were capped at -3. This final score was

1 then applied to the starting grade that had originally been applied to the outcome by default,
2 based on study design. All RCTs started as High and the overall quality became Moderate,
3 Low or Very Low if the overall score was -1, -2 or -3 points respectively. The significance of
4 these overall ratings is explained in Table 4. The reasons for downgrading in each case were
5 specified in the footnotes of the GRADE tables.

6 Non-randomised intervention studies started at Low, and so a score of -1 would be enough
7 to take the grade to the lowest level of Very Low. Non-randomised intervention studies could,
8 however, be upgraded if there was a large magnitude of effect or a dose-response gradient.

9 **Table 4: Overall quality of outcome evidence in GRADE**

Level	Description
High	Further research is very unlikely to change our confidence in the estimate of effect
Moderate	Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
Low	Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
Very low	Any estimate of effect is very uncertain

10 **2.3.4.2 Diagnostic studies**

11 Risk of bias and indirectness of evidence for diagnostic data were evaluated by study using
12 the Quality Assessment of Diagnostic Accuracy Studies version 2 (QUADAS-2) checklists
13 (see appendix H in the NICE guidelines manual 2014²). Risk of bias and applicability in
14 primary diagnostic accuracy studies in QUADAS-2 consists of 4 domains (see Figure 3):

- 15
- 16 • patient selection
 - 17 • index test
 - 18 • reference standard
 - 19 • flow and timing.

19 **Figure 3: Summary of QUADAS-2 with list of signalling, risk of bias and applicability**
20 **questions.**

Domain	Patient selection	Index test	Reference standard	Flow and timing
Description	Describe methods of patient selection. Describe included patients (prior testing, presentation, intended use of index test and setting)	Describe the index test and how it was conducted and interpreted	Describe the reference standard and how it was conducted and interpreted	Describe any patients who did not receive the index test(s) and/or reference standard or who were excluded from the 2x2 table (refer to flow diagram). Describe the time interval and any interventions between index test(s) and reference standard
Signalling questions (yes/no/unclear)	Was a consecutive or random sample of patients enrolled?	Were the index test results interpreted without knowledge of the results of the reference standard?	Is the reference standard likely to correctly classify the target condition?	Was there an appropriate interval between index test(s) and reference standard?

Domain	Patient selection	Index test	Reference standard	Flow and timing
	Was a case-control design avoided?	If a threshold was used, was it pre-specified?	Were the reference standard results interpreted without knowledge of the results of the index test?	Did all patients receive a reference standard?
	Did the study avoid inappropriate exclusions?			Did all patients receive the same reference standard?
				Were all patients included in the analysis?
Risk of bias; (high/low/unclear)	Could the selection of patients have introduced bias?	Could the conduct or interpretation of the index test have introduced bias?	Could the reference standard, its conduct or its interpretation have introduced bias?	Could the patient flow have introduced bias?
Concerns regarding applicability (high/low/unclear)	Are there concerns that the included patients do not match the review question?	Are there concerns that the index test, its conduct, or interpretation differ from the review question?	Are there concerns that the target condition as defined by the reference standard does not match the review question?	

12.3.4.2.1 *Inconsistency*

2 Inconsistency refers to an unexplained heterogeneity of results for an outcome across
3 different studies. Inconsistency was assessed by inspection of the sensitivity (based on the
4 primary measure) using the point estimates and 95% CIs of the individual studies on the
5 forest plots. Particular attention was placed on values above or below 50% (diagnosis based
6 on chance alone) and the threshold set by the committee (the threshold above which it would
7 be acceptable to recommend a test, which for this review was set for sensitivity at 95%). For
8 example, the committee might have set a threshold of 90% as an acceptable level to
9 recommend a test. The evidence was downgraded by 1 increment if the individual studies
10 varied across 2 areas [(for example, 50–90% and 90–100%)] and by 2 increments if the
11 individual studies varied across 3 areas [(for example, 0–50%, 50–90% and 90–100%)].

122.3.4.2.2 *Imprecision*

13 The judgement of precision was based on visual inspection of the confidence region around
14 the summary sensitivity and specificity point from the diagnostic meta-analysis, if a
15 diagnostic meta-analysis was conducted. Where a diagnostic meta-analysis was not
16 conducted, imprecision was assessed according to the range of point estimates or, if only
17 one study contributed to the evidence, the 95% CI around the single study. As a general rule
18 (after discussion with the committee) a variation of 0–20% was considered precise, 20–40%
19 serious imprecision, and >40% very serious imprecision. Imprecision was assessed on the
20 primary outcome measure for decision-making.

212.3.4.2.3 *Overall grading*

22 Quality rating started at High for prospective and retrospective cross-sectional studies, and
23 each major limitation (risk of bias, indirectness, inconsistency and imprecision) brought the
24 rating down by 1 increment to a minimum grade of Very Low, as explained for intervention
25 reviews.

1 **2.3.5 Assessing clinical importance**

2 The committee assessed the evidence by outcome in order to determine if there was, or
3 potentially was, a clinically important benefit, a clinically important harm or no clinically
4 important difference between interventions. To facilitate this, binary outcomes were
5 converted into absolute risk differences (ARDs) using GRADEpro¹ software: the median
6 control group risk across studies was used to calculate the ARD and its 95% CI from the
7 pooled risk ratio.

8 The assessment of clinical benefit, harm, or no benefit or harm was based on the point
9 estimate of absolute effect for intervention studies, which was standardised across the
10 reviews. The committee considered for most of the dichotomous outcomes in the intervention
11 reviews that if at least 50 more participants per 1000 (5%) achieved the outcome of interest
12 in the intervention group compared to the comparison group for a positive outcome then this
13 intervention was considered beneficial. The same point estimate but in the opposite direction
14 applied for a negative outcome. For major adverse events 10 events or more per 1000 (1%)
15 represented clinical harm, and for minor adverse events, 50 events or more per 1000 (5%)
16 represented a clinical harm. For continuous outcomes if the mean difference was greater
17 than the minimally important difference (MID) then this represented a clinical benefit or harm.
18 For outcomes such as mortality any reduction or increase was considered to be clinically
19 important.

20 This assessment was carried out by the committee for each critical outcome, and an
21 evidence summary table was produced to compile the committee's assessments of clinical
22 importance per outcome, alongside the evidence quality and the uncertainty in the effect
23 estimate (imprecision).

24 **2.3.6 Clinical evidence statements**

25 Clinical evidence statements are summary statements that are included in each evidence
26 report, and which summarise the key features of the clinical effectiveness evidence
27 presented. The wording of the evidence statements reflects the certainty or uncertainty in the
28 estimate of effect. The evidence statements are presented by outcome and encompass the
29 following key features of the evidence:

- 30
- 31 • The number of studies and the number of participants for a particular outcome.
 - 32 • An indication of the direction of clinical importance (if one treatment is beneficial or
33 harmful compared to the other, or whether there is no difference between the 2 tested
34 treatments).
 - 35 • A description of the overall quality of the evidence (GRADE overall quality).

35 **2.4 Identifying and analysing evidence of cost effectiveness**

36 The committee is required to make decisions based on the best available evidence of both
37 clinical effectiveness and cost effectiveness. Guideline recommendations should be based
38 on the expected costs of the different options in relation to their expected health benefits
39 (that is, their 'cost effectiveness') rather than the total implementation cost. However, the
40 committee will also need to be increasingly confident in the cost effectiveness of a
41 recommendation as the cost of implementation increases. Therefore, the committee may
42 require more robust evidence on the effectiveness and cost effectiveness of any
43 recommendations that are expected to have a substantial impact on resources; any
44 uncertainties must be offset by a compelling argument in favour of the recommendation. The
45 cost impact or savings potential of a recommendation should not be the sole reason for the
46 committee's decision.²

47 Health economic evidence was sought relating to the key clinical issues being addressed in
48 the guideline. Health economists:

- 1 • Undertook a systematic review of the published economic literature.
- 2 • Undertook new cost-effectiveness analysis in priority areas.

3 **2.4.1 Literature review**

4 The health economists:

- 5 • Identified potentially relevant studies for each review question from the health economic
6 search results by reviewing titles and abstracts. Full papers were then obtained.
- 7 • Reviewed full papers against prespecified inclusion and exclusion criteria to identify
8 relevant studies (see below for details).
- 9 • Critically appraised relevant studies using economic evaluations checklists as specified in
10 the NICE guidelines manual.²
- 11 • Extracted key information about the studies' methods and results into health economic
12 evidence tables (which can be found in appendices to the relevant evidence reports).
- 13 • Generated summaries of the evidence in NICE health economic evidence profile tables
14 (included in the relevant evidence report for each review question) – see below for details.

15 **2.4.1.1 Inclusion and exclusion criteria**

16 Full economic evaluations (studies comparing costs and health consequences of alternative
17 courses of action: cost–utility, cost-effectiveness, cost–benefit and cost–consequences
18 analyses) and comparative costing studies that addressed the review question in the relevant
19 population were considered potentially includable as health economic evidence.

20 Studies that only reported cost per hospital (not per patient), or only reported average cost
21 effectiveness without disaggregated costs and effects were excluded. Literature reviews,
22 abstracts, posters, letters, editorials, comment articles, unpublished studies and studies not
23 in English were excluded. Studies published before 2002 and studies from non-OECD
24 countries or the USA were also excluded, on the basis that the applicability of such studies to
25 the present UK NHS context is likely to be too low for them to be helpful for decision-making.

26 Remaining health economic studies were prioritised for inclusion based on their relative
27 applicability to the development of this guideline and the study limitations. For example, if a
28 high quality, directly applicable UK analysis was available, then other less relevant studies
29 may not have been included. However, in this guideline, no economic studies were excluded
30 on the basis that more applicable evidence was available.

31 For more details about the assessment of applicability and methodological quality see Table
32 5 below and the economic evaluation checklist (appendix H of the NICE guidelines manual²)
33 and the health economics review protocol, which can be found in each of the evidence
34 reports.

35 When no relevant health economic studies were found from the economic literature review,
36 relevant UK NHS unit costs related to the compared interventions were presented to the
37 committee to inform the possible economic implications of the recommendations.

38 **2.4.1.2 NICE health economic evidence profiles**

39 NICE health economic evidence profile tables were used to summarise cost and cost-
40 effectiveness estimates for the included health economic studies in each evidence review
41 report. The health economic evidence profile shows an assessment of applicability and
42 methodological quality for each economic study, with footnotes indicating the reasons for the
43 assessment. These assessments were made by the health economist using the economic
44 evaluation checklist from the NICE guidelines manual.² It also shows the incremental costs,
45 incremental effects (for example, quality-adjusted life years [QALYs]) and incremental cost-

1 effectiveness ratio (ICER) for the base case analysis in the study, as well as information
2 about the assessment of uncertainty in the analysis. See Table 5 for more details.

3 When a non-UK study was included in the profile, the results were converted into pounds
4 sterling using the appropriate purchasing power parity.⁶

5 **Table 5: Content of NICE health economic evidence profile**

Item	Description
Study	Surname of first author, date of study publication and country perspective with a reference to full information on the study.
Applicability	An assessment of applicability of the study to this guideline, the current NHS situation and NICE decision-making: ^(a) <ul style="list-style-type: none"> • Directly applicable – the study meets all applicability criteria, or fails to meet 1 or more applicability criteria but this is unlikely to change the conclusions about cost effectiveness. • Partially applicable – the study fails to meet 1 or more applicability criteria, and this could change the conclusions about cost effectiveness. • Not applicable – the study fails to meet 1 or more of the applicability criteria, and this is likely to change the conclusions about cost effectiveness. Such studies would usually be excluded from the review.
Limitations	An assessment of methodological quality of the study: ^(a) <ul style="list-style-type: none"> • Minor limitations – the study meets all quality criteria, or fails to meet 1 or more quality criteria, but this is unlikely to change the conclusions about cost effectiveness. • Potentially serious limitations – the study fails to meet 1 or more quality criteria, and this could change the conclusions about cost effectiveness. • Very serious limitations – the study fails to meet 1 or more quality criteria, and this is highly likely to change the conclusions about cost effectiveness. Such studies would usually be excluded from the review.
Other comments	Information about the design of the study and particular issues that should be considered when interpreting it.
Incremental cost	The mean cost associated with one strategy minus the mean cost of a comparator strategy.
Incremental effects	The mean QALYs (or other selected measure of health outcome) associated with one strategy minus the mean QALYs of a comparator strategy.
Cost effectiveness	Incremental cost-effectiveness ratio (ICER): the incremental cost divided by the incremental effects (usually in £ per QALY gained).
Uncertainty	A summary of the extent of uncertainty about the ICER reflecting the results of deterministic or probabilistic sensitivity analyses, or stochastic analyses of trial data, as appropriate.

6 (a) *Applicability and limitations were assessed using the economic evaluation checklist in appendix H of the NICE*
7 *guidelines manual*²

8 2.4.2 Undertaking new health economic analysis

9 As well as reviewing the published health economic literature for each review question, as
10 described above, new health economic analysis was undertaken by the health economist in
11 selected areas. Priority areas for new analysis were agreed by the committee after formation
12 of the review questions and consideration of the existing health economic evidence.

13 The committee identified surgery as the highest priority area for original health economic
14 analysis, more specifically, surgery for ureteric stones <10mm, renal stones <10mm and
15 renal stones 10-20mm. These areas were prioritised because there was uncertainty in
16 practice around which intervention to use, and cost trade-offs because the more expensive
17 interventions are also more effective and consequently have less downstream resource use.
18 A full analysis was undertaken for the ureteric stones <10mm. However, following completion

1 of this it was agreed that less formal costing work would be adequate to inform discussions
2 about cost effectiveness for the other strata (small and large renal stones) given the
3 similarities in the effectiveness data and the results of the ureteric stones analysis. The
4 rationale and details of all work undertaken is described in full in the technical report in
5 Appendix 1 and summarised in chapter F.

6 Cost–utility analysis is the preferred methodology for assessing the cost and effectiveness
7 trade-offs in NICE guidelines, however this was considered unfeasible due to too many
8 unknowns on the effectiveness side. Cost analysis was therefore undertaken that aimed to
9 compare the cost of different surgical strategies taking into account both initial intervention
10 costs and downstream resource use due to the need for repeat procedures. However, some
11 exploratory threshold analyses were also undertaken incorporating QALY gains to help
12 inform decision making. This is discussed in more detail in the full technical report in
13 Appendix 1.

14 The following general principles were adhered to in developing the analysis:

- 15 • Methods were consistent with the NICE reference case for interventions with health
16 outcomes in NHS settings.^{2, 4}
- 17 • The committee was involved in the design of the analysis, selection of inputs and
18 interpretation of the results.
- 19 • Inputs were based on the systematic review of the clinical literature supplemented with
20 other published data sources where possible.
- 21 • When published data were not available committee expert opinion was used.
- 22 • Inputs and assumptions were reported fully and transparently.
- 23 • The results were subject to sensitivity analysis and limitations were discussed.
- 24 • The analysis was peer-reviewed by another health economist at the NGC.

25 Full methods and results of the analysis for surgical treatments in people with ureteric stone
26 <10mm are described in a separate economic analysis report. This report also includes
27 details of the considerations and additional cost calculations undertaken to inform decision
28 making for people with small and large renal stones.

29 **2.4.3 Cost-effectiveness criteria**

30 NICE's report 'Social value judgements: principles for the development of NICE guidance'
31 sets out the principles that committees should consider when judging whether an intervention
32 offers good value for money.³ In general, an intervention was considered to be cost effective
33 (given that the estimate was considered plausible) if either of the following criteria applied:

- 34 • the intervention dominated other relevant strategies (that is, it was both less costly in
35 terms of resource use and more clinically effective compared with all the other relevant
36 alternative strategies), or
- 37 • the intervention cost less than £20,000 per QALY gained compared with the next best
38 strategy.

39 If the committee recommended an intervention that was estimated to cost more than £20,000
40 per QALY gained, or did not recommend one that was estimated to cost less than £20,000
41 per QALY gained, the reasons for this decision are discussed explicitly in 'The committee's
42 discussion of the evidence' section of the relevant evidence report, with reference to issues
43 regarding the plausibility of the estimate or to the factors set out in 'Social value judgements:
44 principles for the development of NICE guidance'.³

45 If a study reported the cost per life year gained but not QALYs, the cost per QALY gained
46 was estimated by multiplying by an appropriate utility estimate to aid interpretation. The
47 estimated cost per QALY gained is reported in the health economic evidence profile with a
48 footnote detailing the life-years gained and the utility value used. When QALYs or life years

1 gained are not used in the analysis, results are difficult to interpret unless one strategy
2 dominates the others with respect to every relevant health outcome and cost.

3 **2.4.4 In the absence of health economic evidence**

4 When no relevant published health economic studies were found, and a new analysis was
5 not prioritised, the committee made a qualitative judgement about cost effectiveness by
6 considering expected differences in resource use between options and relevant UK NHS unit
7 costs, alongside the results of the review of clinical effectiveness evidence.

8 The UK NHS costs reported in the guideline are those that were presented to the committee
9 and were correct at the time recommendations were drafted. They may have changed
10 subsequently before the time of publication. However, we have no reason to believe they
11 have changed substantially.

12 **2.5 Developing recommendations**

13 Over the course of the guideline development process, the committee was presented with:

- 14 • Summaries of clinical and health economic evidence and quality (as presented in
15 evidence reports [A–K]).
- 16 • Evidence tables of the clinical and health economic evidence reviewed from the literature.
17 All evidence tables can be found in appendices to the relevant evidence reports.
- 18 • Forest plots and summary ROC curves (in appendices to the relevant evidence reports).
- 19 • A description of the methods and results of the cost-effectiveness analysis undertaken for
20 the guideline (in a separate economic analysis report).

21 Recommendations were drafted on the basis of the committee's interpretation of the
22 available evidence, taking into account the balance of benefits, harms and costs between
23 different courses of action. This was either done formally in an economic model, or
24 informally. Firstly, the net clinical benefit over harm (clinical effectiveness) was considered,
25 focusing on the critical outcomes. When this was done informally, the committee took into
26 account the clinical benefits and harms when one intervention was compared with another.
27 The assessment of net clinical benefit was moderated by the importance placed on the
28 outcomes (the committee's values and preferences), and the confidence the committee had
29 in the evidence (evidence quality). Secondly, the committee assessed whether the net
30 clinical benefit justified any differences in costs between the alternative interventions.

31 When clinical and health economic evidence was of poor quality, conflicting or absent, the
32 committee drafted recommendations based on its expert opinion. The considerations for
33 making consensus-based recommendations include the balance between potential harms
34 and benefits, the economic costs compared to the economic benefits, current practices,
35 recommendations made in other relevant guidelines, patient preferences and equality issues.
36 The consensus recommendations were agreed through discussions in the committee. The
37 committee also considered whether the uncertainty was sufficient to justify delaying making a
38 recommendation to await further research, taking into account the potential harm of failing to
39 make a clear recommendation (see section 2.5.1 below).

40 The committee considered the appropriate 'strength' of each recommendation. This takes
41 into account the quality of the evidence but is conceptually different. Some recommendations
42 are 'strong' in that the committee believes that the vast majority of healthcare and other
43 professionals and patients would choose a particular intervention if they considered the
44 evidence in the same way that the committee has. This is generally the case if the benefits
45 clearly outweigh the harms for most people and the intervention is likely to be cost effective.
46 However, there is often a closer balance between benefits and harms, and some patients
47 would not choose an intervention whereas others would. This may happen, for example, if
48 some patients are particularly averse to some side effect and others are not. In these

1 circumstances the recommendation is generally weaker, although it may be possible to make
2 stronger recommendations about specific groups of patients.

3 The committee focused on the following factors in agreeing the wording of the
4 recommendations:

- 5 • The actions health professionals need to take.
- 6 • The information readers need to know.
- 7 • The strength of the recommendation (for example the word 'offer' was used for strong
8 recommendations and 'consider' for weaker recommendations).
- 9 • The involvement of patients (and their carers if needed) in decisions on treatment and
10 care.
- 11 • Consistency with NICE's standard advice on recommendations about drugs, waiting times
12 and ineffective interventions (see section 9.2 in the NICE guidelines manual²).

13 The main considerations specific to each recommendation are outlined in 'The committee's
14 discussion of the evidence' section within each evidence report.

15 **2.5.1 Research recommendations**

16 When areas were identified for which good evidence was lacking, the committee considered
17 making recommendations for future research. Decisions about the inclusion of a research
18 recommendation were based on factors such as:

- 19 • the importance to patients or the population
- 20 • national priorities
- 21 • potential impact on the NHS and future NICE guidance
- 22 • ethical and technical feasibility.

23 **2.5.2 Validation process**

24 This guidance is subject to a 6-week public consultation and feedback as part of the quality
25 assurance and peer review of the document. All comments received from registered
26 stakeholders are responded to in turn and posted on the NICE website.

27 **2.5.3 Updating the guideline**

28 Following publication, and in accordance with the NICE guidelines manual, NICE will
29 undertake a review of whether the evidence base has progressed significantly to alter the
30 guideline recommendations and warrant an update.

31 **2.5.4 Disclaimer**

32 Healthcare providers need to use clinical judgement, knowledge and expertise when
33 deciding whether it is appropriate to apply guidelines. The recommendations cited here are a
34 guide and may not be appropriate for use in all situations. The decision to adopt any of the
35 recommendations cited here must be made by practitioners in light of individual patient
36 circumstances, the wishes of the patient, clinical expertise and resources.

37 The National Guideline Centre disclaims any responsibility for damages arising out of the use
38 or non-use of this guideline and the literature used in support of this guideline.

39 **2.5.5 Funding**

40 The National Guideline Centre was commissioned by the National Institute for Health and
41 Care Excellence to undertake the work on this guideline.

3 Additional information: Expert testimony on paediatric care in renal and ureteric stones

The lay member representation providing a paediatric perspective on the committee was available for the whole of the development period of the guideline, and this resulted in a gap in the representation of the experiences of children and young people. Little published research evidence was found for children for the questions reviewed, and when this is the case guideline committee members may invite expert witnesses to the group to provide their and knowledge and experience to help inform the committee when drawing up recommendations for this population.

An expert witness was invited to speak to the committee from their own experience as a parent of children with recurring stones with reference specifically to the following areas:

- What procedures were carried out to diagnose the stones?
- What treatments their children have received, such as:
 - drugs for managing pain.
 - drugs to help the stone pass such as an alpha blocker or calcium channel blocker?
 - Any surgical procedures performed
- Was a choice of treatments offered?
- Was any stone analysis carried out or other tests performed after the stones were removed?
- What follow-up care has been provided?

Full details of the expert testimony are available in Appendix 3.

1 4 Acronyms and abbreviations

Term	Definition
PNL	Percutaneous Nephrolithotomy
MPL	Methylprednisolone
NAG	N-Acetyl-Beta-D-Glucosaminidase
AKI	Acute Kidney Injury
APRT	Adenine Phosphoribosyltransferase Deficiency
BAUS	British Association of Urological Surgeons
B-TFE	Balanced Turbo Field Echo, MRI Related.
CRD	Centre for Research and Dissemination
CT	Computerised Tomography
CT KUB	CT of the Kidneys, Ureters and Bladder
DASH	Dietary Approaches to Stop Hypertension
EQ5D	Euroqol Five-Dimension Scale
ESWL	Extracorporeal Shock Wave Lithotripsy
GI	Gastrointestinal
HTA	Health Technology Assessment
IM	Intramuscular
IV	Intravenous
mAs	Milliamperage-Seconds
mEq	Milliequivalents Per Litre
MET	Medical Expulsive Therapy
MPR	Multiplanar Reformation
MRI	Magnetic Resonance Imaging
MRU	Magnetic Resonance Urography
NCCT	Non-Contrast Computerised Tomography
NHS-EED	NHS Economic Evaluation Database
Non-contrast HASTE	Half Fourier Acquisition Single Shot Turbo Spin Echo
NRS	Numerical Rating Scale
NSAID	Nonsteroidal Anti-Inflammatory Drugs
OECD	Organisation for Economic Co-Operation and Development
OPCS	Office of Population Censuses and Surveys
PCNL	Percutaneous Nephrolithotomy
PHPT	Para Hyperparathyroidism
PSSRU	Personal Social Services Research Unit
RIRS	Retrograde Intrarenal Surgery
RNUS	Retrograde Nephroureteral Stent
SUSPEND Trial	Spontaneous Urinary Stone Passage Enabled by Drugs Trial
SWL	Shock Wave Lithotripsy
UHCT	Unenhanced Helical Computerised Tomography
URS	Ureteroscopy for Urolithiasis
USG	Urologist Operated Ultrasound

2

1 5 Glossary

2 The NICE Glossary can be found at www.nice.org.uk/glossary.

3 5.1 Guideline-specific terms

Term	Definition
Acute pulmonary edema	A condition requiring immediate medical treatment, in which the air sacs in the lungs become filled with fluid (oedema), impairing the lungs' ability to oxygenate blood.
Adenine phosphoribosyltransferase deficiency	An inherited genetic metabolic disorder associated with a mutation in the enzyme.
Anaphylaxis	An allergic reaction that is rapid in onset and may cause death.
Apnea	Suspension of breathing. During apnoea, there is no movement of the muscles of inhalation and the volume of the lungs initially remains unchanged.
Balanced turbo field echo (b-tfe)	In MRI (Magnetic Resonance Imaging) scanning, a b-tfe is a gradient echo pulse sequence, with a balanced gradient waveform and data acquisition, after an initial preparation pulse for contrast enhancement.
Brushite	The phosphate mineral in calcium phosphate kidney stones.
Calcium renal lithiasis	The formation of calcium stones in the kidney. This is a frequent condition that has a high recurrence rate. Different metabolic changes may trigger the onset of calcium stone disorders, such as hypercalciuria, hyperoxaluria, hyperuricosuria, hypocitraturia and others.
Calculi	'Stones' in the urinary system are called urinary calculi and include kidney stones (also called renal calculi or nephroliths) and bladder stones (also called vesical calculi or cystoliths). They can be composed of various substances, or a mixture of several substances. Oxalate and urate stones are amongst the most common.
Calculosis	A condition marked by formation of calculi and 'concretions' (see below).
Computerised tomography scan (CT scan)	The use of X-rays and a computer to create detailed images of the inside of the body.
Concretions	Hard, solid masses.
Creatininaemia	Having a high creatinine concentration. Serum creatinine (a blood measurement) is an important indicator of kidney function. As the kidneys become impaired for any reason, the creatinine level in the blood will rise due to poor clearance of creatinine by the kidneys. Creatininaemia signifies impaired kidney function or kidney disease.
CT kub	CT scan of the kidneys, ureters and bladder, is a common investigation of choice, for adults who have acute renal colic.
Cystine	A white solid, slightly soluble in water. It serves two biological functions: a site of redox reactions and a mechanical linkage that allows proteins to retain their three-dimensional structure.
Cystinuria	The most common defect in the transport of an amino acid. Although cystine is not the only overly excreted amino acid in cystinuria, it is the least soluble of all naturally occurring amino acids. Cystine tends to precipitate out of urine and form stones (calculi) in the urinary tract.

Term	Definition
Cystoscopically	Employing cystoscopy. Cystoscopy is endoscopy of (looking inside – see below) the urinary bladder via the ‘urethra’ (see below). It is carried out with a cystoscope.
Diabetes mellitus	Commonly referred to as diabetes, diabetes mellitus is a group of metabolic disorders in which there are high blood sugar levels over a prolonged period.
Dysuria	Painful or difficult urination.
Echotomography	A form of tomography (see ‘computerised tomography’ above), which detects acoustic (usually ultrasonic) reflections from variations in ‘acoustic impedance’ (measures of the opposition that a system presents to the flow of sound).
Endocrinologic (endocrinological)	Involving or relating to the endocrine glands or secretions, or to ‘endocrinology’ (the field of hormone related diseases).
Endoscopic	Pertaining to endoscopy. Endoscopy involves looking inside a hollow organ or a body cavity with an endoscope. Endoscopy can be used to look at a stone in the kidneys or urinary tract (see below). [See ‘ureteroscopy’ below, to understand how an endoscope can be used to remove a stone.]
EQ-5D	A standardised way of measuring the quality of life of a ‘population’ (the subjects of a particular study). EQ-5D is NICE’s preferred measure.
Extracorporeal shockwave lithotripsy (ESL)	A procedure that uses high-energy shock waves to break down kidney stones into small crystals.
Extravasation	The leakage of a fluid out of its container. In the case of inflammation, it refers to the movement of white blood cells from the capillaries to the tissues surrounding them (leukocyte extravasation), also known as diapedesis.
Foley catheter	A flexible tube, which a clinician passes through the urethra (see below) and into the bladder to drain urine. It is the most common type of urinary catheter.
Gastrointestinal	Relating to the stomach and the intestines
Genitourological	Related to the genitourinary (or ‘urogenital’) system, which is the organ system of the reproductive organs and the urinary tract. Reproductive organs and urinary tract are grouped together because of their nearness to one other, their common origin before birth, and their use of common pathways, like the male urethra (see below).
Haematuria (Hematuria)	Blood in urine. ‘Microscopic haematuria’ is invisible to the naked eye and is often found incidentally when urine is analysed (‘urinalysis’). Any part of the kidneys or urinary tract (ureters, urinary bladder, prostate, and urethra) can leak blood into the urine.
Haemorrhagic (Hemorrhagic)	Accompanied or produced by haemorrhage (an escape of blood from a ruptured blood vessel).
Hydronephrosis	The swelling of a kidney, due to a build-up of urine. It happens when urine cannot drain out from the kidney to the bladder, because of a blockage or obstruction. This can occur in one or both kidneys.
Hydroureteronephrosis	The situation where, most commonly, a blockage of urinary flow toward the bladder causes the kidney and ureter to swell. This may be ‘unilateral’, affecting just one kidney and ureter, or ‘bilateral’, affecting both.’ Kidney function is frequently damaged by this.
Hyper-uricosuria	The presence of excessive amounts of uric acid in the urine.

Term	Definition
Hypercalcaemia	A high calcium level in the blood serum.
Hypercalcinuria	See 'hypercalciuria' below.
Hypercalciuria (Hypercalcinuria)	Elevated calcium in the urine. Chronic (extended over time) hypercalciuria may lead to long-term damage to kidney function, nephrocalcinosis (see below), or renal insufficiency (poor kidney function for the time being). Patients with hypercalciuria have kidneys that put out higher levels of calcium than normal.
Hyperdense	This is terminology largely used in describing computerised tomographies (CT). If an abnormality is bright (white) on CT, we describe it as hyperdense.
Hyperkalaemia (Hyperkalemia)	A potassium level in blood that is higher than normal.
Hyperoxaluria	An excessive urinary excretion of oxalate. Individuals with hyperoxaluria often have calcium oxalate kidney stones.
Hyperparathyroidism	Condition in which the parathyroid glands, which are in the neck near the thyroid gland, produce too much parathyroid hormone. This causes hypercalcaemia (see above), which, left untreated, can lead to a range of health problems.
Hyperpotassaemia (Hyperpotassemia)	An excess of potassium in the bloodstream.
Hyperuricaemia (Hyperuricemia)	An excess of uric acid in the blood. Uric acid passes through the liver, and enters the bloodstream. Most of it is excreted (removed from the body) in urine, or passes through the intestines to regulate "normal" levels.
Hypouricaemia (Hypouricemia)	A below-normal level of uric acid in blood serum.
Hypocitraturia/ hypocitraturic	Low urinary citrate excretion, a known risk factor for the development of kidney stones.
Hypomagnesemia	A disturbance in which there is a low level of magnesium in the blood.
Hypouricosuria	The presence of an unusually low amount of uric acid in the urine.
Infrared spectrophotometry	This is used to identify and study chemicals. It involves a range of techniques, mostly based on what is called 'absorption spectroscopy.'
Intracorporeal lithotripsy	A procedure carried out under endoscopic control, for fragmenting urinary calculi.
Juxtavesical	Situated near or adjoining the urinary bladder.
Laboratory tests.	Procedures that involve testing a sample of any bodily fluid or substance. Tests results help physicians, with diagnosis and can guide the planning of future interventions, help medical practitioners check the effectiveness of treatment, or monitor disease progress.
Leukocytosis	An increase in the number of white cells in the blood, especially during an infection.
Lithiasis	The formation of stones or gravel in the human body, especially in the urinary passages.
Lithotripsy	The procedure for destroying hard masses, like kidney stones.
Medical expulsive therapy	The use of alpha blocker medicines to expedite the passage of kidney stones which are located in the ureter.
Metabolic tests.	Tests that provide doctors with information about the body's fluid balance. They help with assessing how the kidneys and liver are functioning.
Midureteric	The portion of the ureter which overlies the bony pelvis.

Term	Definition
Multiplanar reformation	A process for reconstructing images, so that they can be viewed on several different planes.
N-acetyl-beta-D-glucosaminidase (NAG)	A sensitive marker for disorders of kidney function
Natriuresis	Excretion of sodium in the urine.
Nephrocalcinosis	Term originally used to describe deposition of calcium salts in the renal parenchyma due to hyperparathyroidism.
Nephrolithiasis	The formation of a stone in the kidney or lower in the urinary tract.
Nocturia	The situation where an individual wakes at night one or more times to pass urine.
Non-radiopaque	Radiopaque dyes are metal based and used in radiology to enhance X-ray pictures of internal anatomic (body) structures. Non-radiopaque, unlike traditional metals, are transparent to x-rays.
Normocalciuric	Having a normal amount of calcium in the urine.
Obstructive uropathy	This occurs when urine cannot drain through a ureter (a tube that carries urine from the kidneys to the bladder).
Oxalate	A salt of oxalic acid.
Peptic ulcer	An area of damage to the inner lining of the stomach or the upper part of the intestine.
Percutaneous nephrolithotomy	A minimally-invasive procedure to remove stones from the kidney by a small puncture wound through the skin.
Ph/urine analysis	Urine analysis that measures the level of alkaline in a sample. The higher the number, the more basic (alkaline) it is. The lower the number, the more acidic the urine is considered to be, which could indicate an environment conducive to kidney stones.
Pneumatic lithoclast	Simultaneous ultrasonic and pneumatic lithotripsy
Pyelolithotomy	Surgical incision of the renal pelvis of a kidney for removal of a kidney stone - called also pelviolithotomy.
Pyeloureteral	The pyeloureteric junction joins the ureter and the renal pelvis (the region in the kidney in which the urine produced by the kidney is stored).
Pyleography	A form of imaging of the renal pelvis and ureter.
Renal tubular acidosis	A disease that occurs when the kidneys fail to excrete acids into the urine, which causes a person's blood to remain too acidic.
Retrograde Nephroureteral Stent (RNUS)	A catheter placed in patients who have undergone surgical treatment, such as cystectomy with ileal conduit formation in which it exits from the conduit and extends retrograde to the renal pelvis.
Spasmolytics	Type of muscle relaxant.
Sphygmomanometer	An instrument for measuring blood pressure, which can be used by clinicians or patients.
Stone analysis	Evaluating the composition of a kidney stone, to help determine the cause of its formation and to guide treatment.
Stone disease	Also known as urolithiasis, is when a solid piece of material (kidney stone) occurs in the urinary tract. Kidney stones typically form in the kidney and leave the body in the urine stream. A small stone may pass without causing symptoms.
Submucosal dissection	An advanced surgical procedure using endoscopy to remove gastrointestinal tumours that have not entered the muscle layer.
Thiazides	These are the most commonly used diuretics. Diuretics increase the production of urine.

Term	Definition
Transrectal	Pertaining to the prostate gland and the surrounding tissue.
Transvaginal	Pertaining to female reproductive organs. These include the uterus, fallopian tubes, ovaries, cervix, and vagina.
Ureter	A thin tube connecting a kidney with the bladder.
Ureterography	Radiography of the ureter, after injection of a contrast medium.
Ureterohydronephrosis	Dilatation (abnormal enlargement) of the ureter and the pelvis of the kidney resulting from a mechanical or inflammatory obstruction in the urinary tract.
Ureterolithiasis	When a calculus is located in the ureter.
Ureteroscopy	Treatment for small stones within the kidney using a very thin flexible telescope that can be passed up from the female urethra, or end of the penis in a man, into the bladder and up the ureter.
Ureterovesical	Relating to the entry point of the ureter into the urinary bladder.
Urethra	The tube connecting the urinary bladder with the outer surface of the body.
Urethrostenosis	Abnormal narrowing of the urethra.
Uric acid stones	One of four major types of kidney stones, which include calcium stones (calcium oxalate and calcium phosphate), struvite stones, and cystine stones.
Urinary calculi	Urinary calculi are solid particles in the urinary system. They may cause pain, nausea, vomiting, haematuria, and, possibly, chills and fever due to secondary infection.
Urolithiasis	The formation of stony concretions in the bladder or urinary tract.
Urosepsis	Sepsis, (a response to infection causing tissue or organ damage), with a source localised to the urinary tract (or male genital tract, e.g. prostate).
URS	The use of an endoscope passed in to the ureter to visualise and treat the stone. Stones in the distal and proximal ureter are treated with semi rigid ureteroscopy (URS). Difficult stones in the proximal ureter and stones in the kidney can be treated with flexible ureteroscopy (FURS). Treatment of renal stones with the flexible ureteroscope can be referred to as retrograde intra renal surgery (RIRS).

1 5.2 General and methodological terms

Term	Definition
Abstract	Summary of a study, which may be published alone or as an introduction to a full scientific paper.
Algorithm (in guidelines)	A flow chart of the clinical decision pathway described in the guideline, where decision points are represented with boxes, linked with arrows.
Allocation concealment	The process used to prevent advance knowledge of group assignment in an RCT. The allocation process should be impervious to any influence by the individual making the allocation, by being administered by someone who is not responsible for recruiting participants.
Applicability	How well the results of a study or NICE evidence review can answer a clinical question or be applied to the population being considered.
Arm (of a clinical study)	Subsection of individuals within a study who receive one particular intervention, for example placebo arm.

Term	Definition
Association	Statistical relationship between 2 or more events, characteristics or other variables. The relationship may or may not be causal.
Base case analysis	In an economic evaluation, this is the main analysis based on the most plausible estimate of each input. In contrast, see Sensitivity analysis.
Baseline	The initial set of measurements at the beginning of a study (after run-in period where applicable), with which subsequent results are compared.
Bayesian analysis	A method of statistics, where a statistic is estimated by combining established information or belief (the 'prior') with new evidence (the 'likelihood') to give a revised estimate (the 'posterior').
Before-and-after study	A study that investigates the effects of an intervention by measuring particular characteristics of a population both before and after taking the intervention, and assessing any change that occurs.
Bias	Influences on a study that can make the results look better or worse than they really are. (Bias can even make it look as if a treatment works when it does not.) Bias can occur by chance, deliberately or as a result of systematic errors in the design and execution of a study. It can also occur at different stages in the research process, for example, during the collection, analysis, interpretation, publication or review of research data. For examples see selection bias, performance bias, information bias, confounding factor, and publication bias.
Blinding	A way to prevent researchers, doctors and patients in a clinical trial from knowing which study group each patient is in so they cannot influence the results. The best way to do this is by sorting patients into study groups randomly. The purpose of 'blinding' or 'masking' is to protect against bias. A single-blinded study is one in which patients do not know which study group they are in (for example whether they are taking the experimental drug or a placebo). A double-blinded study is one in which neither patients nor the researchers and doctors know which study group the patients are in. A triple blind study is one in which neither the patients, clinicians or the people carrying out the statistical analysis know which treatment patients received.
Carer (caregiver)	Someone who looks after family, partners or friends in need of help because they are ill, frail or have a disability.
Case-control study	A study to find out the cause(s) of a disease or condition. This is done by comparing a group of patients who have the disease or condition (cases) with a group of people who do not have it (controls) but who are otherwise as similar as possible (in characteristics thought to be unrelated to the causes of the disease or condition). This means the researcher can look for aspects of their lives that differ to see if they may cause the condition. For example, a group of people with lung cancer might be compared with a group of people the same age that do not have lung cancer. The researcher could compare how long both groups had been exposed to tobacco smoke. Such studies are retrospective because they look back in time from the outcome to the possible causes of a disease or condition.
Case series	Report of a number of cases of a given disease, usually covering the course of the disease and the response to treatment. There is no comparison (control) group of patients.
Clinical efficacy	The extent to which an intervention is active when studied under controlled research conditions.

Term	Definition
Clinical effectiveness	How well a specific test or treatment works when used in the 'real world' (for example, when used by a doctor with a patient at home), rather than in a carefully controlled clinical trial. Trials that assess clinical effectiveness are sometimes called management trials. Clinical effectiveness is not the same as efficacy.
Clinician	A healthcare professional who provides patient care. For example, a doctor, nurse or physiotherapist.
Cochrane Review	The Cochrane Library consists of a regularly updated collection of evidence-based medicine databases including the Cochrane Database of Systematic Reviews (reviews of randomised controlled trials prepared by the Cochrane Collaboration).
Cohort study	A study with 2 or more groups of people – cohorts – with similar characteristics. One group receives a treatment, is exposed to a risk factor or has a particular symptom and the other group does not. The study follows their progress over time and records what happens. See also observational study.
Comorbidity	A disease or condition that someone has in addition to the health problem being studied or treated.
Comparability	Similarity of the groups in characteristics likely to affect the study results (such as health status or age).
Concordance	This is a recent term whose meaning has changed. It was initially applied to the consultation process in which doctor and patient agree therapeutic decisions that incorporate their respective views, but now includes patient support in medicine taking as well as prescribing communication. Concordance reflects social values but does not address medicine-taking and may not lead to improved adherence.
Confidence interval (CI)	<p>There is always some uncertainty in research. This is because a small group of patients is studied to predict the effects of a treatment on the wider population. The confidence interval is a way of expressing how certain we are about the findings from a study, using statistics. It gives a range of results that is likely to include the 'true' value for the population.</p> <p>The CI is usually stated as '95% CI', which means that the range of values has a 95 in a 100 chance of including the 'true' value. For example, a study may state that "based on our sample findings, we are 95% certain that the 'true' population blood pressure is not higher than 150 and not lower than 110". In such a case the 95% CI would be 110 to 150.</p> <p>A wide confidence interval indicates a lack of certainty about the true effect of the test or treatment – often because a small group of patients has been studied. A narrow confidence interval indicates a more precise estimate (for example, if a large number of patients have been studied).</p>
Confounding factor	<p>Something that influences a study and can result in misleading findings if it is not understood or appropriately dealt with.</p> <p>For example, a study of heart disease may look at a group of people that exercises regularly and a group that does not exercise. If the ages of the people in the 2 groups are different, then any difference in heart disease rates between the 2 groups could be because of age rather than exercise. Therefore age is a confounding factor.</p>
Consensus methods	Techniques used to reach agreement on a particular issue. Consensus methods may be used to develop NICE guidance if there is not enough good quality research evidence to give a clear answer to a question. Formal consensus methods include Delphi and nominal group techniques.

Term	Definition
Control group	<p>A group of people in a study who do not receive the treatment or test being studied. Instead, they may receive the standard treatment (sometimes called 'usual care') or a dummy treatment (placebo). The results for the control group are compared with those for a group receiving the treatment being tested. The aim is to check for any differences.</p> <p>Ideally, the people in the control group should be as similar as possible to those in the treatment group, to make it as easy as possible to detect any effects due to the treatment.</p>
Cost–benefit analysis (CBA)	<p>Cost–benefit analysis is one of the tools used to carry out an economic evaluation. The costs and benefits are measured using the same monetary units (for example, pounds sterling) to see whether the benefits exceed the costs.</p>
Cost comparison	<p>Cost comparison is one of the tools used to carry out an economic evaluation. It compares only the costs of alternative interventions (including the costs of managing any consequences of the intervention in terms of for example adverse events or downstream resource use from the effectiveness of the interventions).</p>
Cost-offset calculations	<p>When comparing two alternative; the difference in costs of providing an interventions, minus the difference in downstream costs.</p> <p>For example; intervention A may be initially cheaper, but lead to more downstream resource use because it is less effective, versus intervention B. If the downstream resource use saving from intervention B outweighs its higher intervention cost, then the cost offset would be negative meaning the initial cost has been offset and intervention B would be an overall cheaper intervention.</p>
Cost–consequences analysis (CCA)	<p>Cost–consequences analysis is one of the tools used to carry out an economic evaluation. This compares the costs (such as treatment and hospital care) and the consequences (such as health outcomes) of a test or treatment with a suitable alternative. Unlike cost–benefit analysis or cost-effectiveness analysis, it does not attempt to summarise outcomes in a single measure (like the quality-adjusted life year) or in financial terms. Instead, outcomes are shown in their natural units (some of which may be monetary) and it is left to decision-makers to determine whether, overall, the treatment is worth carrying out.</p>
Cost-effectiveness analysis (CEA)	<p>Cost-effectiveness analysis is one of the tools used to carry out an economic evaluation. The benefits are expressed in non-monetary terms related to health, such as symptom-free days, heart attacks avoided, deaths avoided or life years gained (that is, the number of years by which life is extended as a result of the intervention).</p>
Cost-effectiveness model	<p>An explicit mathematical framework, which is used to represent clinical decision problems and incorporate evidence from a variety of sources in order to estimate the costs and health outcomes.</p>
Cost–utility analysis (CUA)	<p>Cost–utility analysis is one of the tools used to carry out an economic evaluation. The benefits are assessed in terms of both quality and duration of life, and expressed as quality-adjusted life years (QALYs). See also utility.</p>
Credible interval (CrI)	<p>The Bayesian equivalent of a confidence interval.</p>
Decision analysis	<p>An explicit quantitative approach to decision-making under uncertainty, based on evidence from research. This evidence is translated into probabilities, and then into diagrams or decision trees which direct the clinician through a succession of possible scenarios, actions and outcomes.</p>
Deterministic analysis	<p>In economic evaluation, this is an analysis that uses a point estimate for each input. In contrast, see Probabilistic analysis</p>

Term	Definition
Diagnostic odds ratio	The diagnostic odds ratio is a measure of the effectiveness of a diagnostic test. It is defined as the ratio of the odds of the test being positive if the subject has a disease relative to the odds of the test being positive if the subject does not have the disease.
Discounting	Costs and perhaps benefits incurred today have a higher value than costs and benefits occurring in the future. Discounting health benefits reflects individual preference for benefits to be experienced in the present rather than the future. Discounting costs reflects individual preference for costs to be experienced in the future rather than the present.
Disutility	The loss of quality of life associated with having a disease or condition. See Utility
Dominance	A health economics term. When comparing tests or treatments, an option that is both less effective and costs more is said to be 'dominated' by the alternative.
Drop-out	A participant who withdraws from a trial before the end.
Economic evaluation	An economic evaluation is used to assess the cost effectiveness of healthcare interventions (that is, to compare the costs and benefits of a healthcare intervention to assess whether it is worth doing). The aim of an economic evaluation is to maximise the level of benefits – health effects – relative to the resources available. It should be used to inform and support the decision-making process; it is not supposed to replace the judgement of healthcare professionals. There are several types of economic evaluation: cost–benefit analysis, cost–consequences analysis, cost-effectiveness analysis, cost-minimisation analysis and cost–utility analysis. They use similar methods to define and evaluate costs, but differ in the way they estimate the benefits of a particular drug, programme or intervention.
Effect (as in effect measure, treatment effect, estimate of effect, effect size)	A measure that shows the magnitude of the outcome in one group compared with that in a control group. For example, if the absolute risk reduction is shown to be 5% and it is the outcome of interest, the effect size is 5%. The effect size is usually tested, using statistics, to find out how likely it is that the effect is a result of the treatment and has not just happened by chance (that is, to see if it is statistically significant).
Effectiveness	How beneficial a test or treatment is under usual or everyday conditions, compared with doing nothing or opting for another type of care.
Efficacy	How beneficial a test, treatment or public health intervention is under ideal conditions (for example, in a laboratory), compared with doing nothing or opting for another type of care.
Epidemiological study	The study of a disease within a population, defining its incidence and prevalence and examining the roles of external influences (for example, infection, diet) and interventions.
EQ-5D (EuroQol 5 dimensions)	A standardised instrument used to measure health-related quality of life. It provides a single index value for health status.
Evidence	Information on which a decision or guidance is based. Evidence is obtained from a range of sources including randomised controlled trials, observational studies, expert opinion (of clinical professionals or patients).
Exclusion criteria (literature review)	Explicit standards used to decide which studies should be excluded from consideration as potential sources of evidence.
Exclusion criteria (clinical study)	Criteria that define who is not eligible to participate in a clinical study.

Term	Definition
Extended dominance	If Option A is both more clinically effective than Option B and has a lower cost per unit of effect, when both are compared with a doing-nothing alternative then Option A is said to have extended dominance over Option B. Option A is therefore cost effective and should be preferred, other things remaining equal.
Extrapolation	An assumption that the results of studies of a specific population will also hold true for another population with similar characteristics.
Follow-up	Observation over a period of time of an individual, group or initially defined population whose appropriate characteristics have been assessed in order to observe changes in health status or health-related variables.
Generalisability	The extent to which the results of a study hold true for groups that did not participate in the research. See also external validity.
Gold standard	A method, procedure or measurement that is widely accepted as being the best available to test for or treat a disease.
GRADE, GRADE profile	A system developed by the GRADE Working Group to address the shortcomings of present grading systems in healthcare. The GRADE system uses a common, sensible and transparent approach to grading the quality of evidence. The results of applying the GRADE system to clinical trial data are displayed in a table known as a GRADE profile.
Harms	Adverse effects of an intervention.
Health economics	Study or analysis of the cost of using and distributing healthcare resources.
Health-related quality of life (HRQoL)	A measure of the effects of an illness to see how it affects someone's day-to-day life.
Heterogeneity or Lack of homogeneity	The term is used in meta-analyses and systematic reviews to describe when the results of a test or treatment (or estimates of its effect) differ significantly in different studies. Such differences may occur as a result of differences in the populations studied, the outcome measures used or because of different definitions of the variables involved. It is the opposite of homogeneity.
Imprecision	Results are imprecise when studies include relatively few patients and few events and thus have wide confidence intervals around the estimate of effect.
Inclusion criteria (literature review)	Explicit criteria used to decide which studies should be considered as potential sources of evidence.
Incremental analysis	The analysis of additional costs and additional clinical outcomes with different interventions.
Incremental cost	The extra cost linked to using one test or treatment rather than another. Or the additional cost of doing a test or providing a treatment more frequently.
Incremental cost-effectiveness ratio (ICER)	The difference in the mean costs in the population of interest divided by the differences in the mean outcomes in the population of interest for one treatment compared with another.
Incremental net benefit (INB)	The value (usually in monetary terms) of an intervention net of its cost compared with a comparator intervention. The INB can be calculated for a given cost-effectiveness (willingness to pay) threshold. If the threshold is £20,000 per QALY gained then the INB is calculated as: $(£20,000 \times \text{QALYs gained}) - \text{Incremental cost}$.
Indirectness	The available evidence is different to the review question being addressed, in terms of PICO (population, intervention, comparison and outcome).

Term	Definition
Intention-to-treat analysis (ITT)	An assessment of the people taking part in a clinical trial, based on the group they were initially (and randomly) allocated to. This is regardless of whether or not they dropped out, fully complied with the treatment or switched to an alternative treatment. Intention-to-treat analyses are often used to assess clinical effectiveness because they mirror actual practice: that is, not everyone complies with treatment and the treatment people receive may be changed according to how they respond to it.
Intervention	In medical terms this could be a drug treatment, surgical procedure, diagnostic or psychological therapy. Examples of public health interventions could include action to help someone to be physically active or to eat a more healthy diet.
Intraoperative	The period of time during a surgical procedure.
Kappa statistic	A statistical measure of inter-rater agreement that takes into account the agreement occurring by chance.
Length of stay	The total number of days a participant stays in hospital.
Licence	See 'Product licence'.
Life years gained	Mean average years of life gained per person as a result of the intervention compared with an alternative intervention.
Likelihood ratio	The likelihood ratio combines information about the sensitivity and specificity. It tells you how much a positive or negative result changes the likelihood that a patient would have the disease. The likelihood ratio of a positive test result (LR+) is sensitivity divided by (1 minus specificity).
Long-term care	Residential care in a home that may include skilled nursing care and help with everyday activities. This includes nursing homes and residential homes.
Logistic regression or Logit model	In statistics, logistic regression is a type of analysis used for predicting the outcome of a binary dependent variable based on one or more predictor variables. It can be used to estimate the log of the odds (known as the 'logit').
Loss to follow-up	A patient, or the proportion of patients, actively participating in a clinical trial at the beginning, but whom the researchers were unable to trace or contact by the point of follow-up in the trial
Markov model	A method for estimating long-term costs and effects for recurrent or chronic conditions, based on health states and the probability of transition between them within a given time period (cycle).
Meta-analysis	A method often used in systematic reviews. Results from several studies of the same test or treatment are combined to estimate the overall effect of the treatment.
Multivariate model	A statistical model for analysis of the relationship between 2 or more predictor (independent) variables and the outcome (dependent) variable.
Negative predictive value (NPV)	In screening or diagnostic tests: A measure of the usefulness of a screening or diagnostic test. It is the proportion of those with a negative test result who do not have the disease, and can be interpreted as the probability that a negative test result is correct. It is calculated as follows: $TN/(TN+FN)$
Net monetary benefit (NMB)	The value in monetary terms of an intervention net of its cost. The NMB can be calculated for a given cost-effectiveness threshold. If the threshold is £20,000 per QALY gained then the NMB for an intervention is calculated as: $(£20,000 \times \text{mean QALYs}) - \text{mean cost}$. The most preferable option (that is, the most clinically effective option to have an ICER below the threshold selected) will be the treatment with the highest NMB.

Term	Definition
Non-randomised intervention study	<p>A quantitative study investigating the effectiveness of an intervention that does not use randomisation to allocate patients (or units) to treatment groups. Non-randomised studies include observational studies, where allocation to groups occurs through usual treatment decisions or people's preferences. Non-randomised studies can also be experimental, where the investigator has some degree of control over the allocation of treatments.</p> <p>Non-randomised intervention studies can use a number of different study designs, and include cohort studies, case-control studies, controlled before-and-after studies, interrupted-time-series studies and quasi-randomised controlled trials.</p>
Number needed to treat (NNT)	<p>The average number of patients who need to be treated to get a positive outcome. For example, if the NNT is 4, then 4 patients would have to be treated to ensure 1 of them gets better. The closer the NNT is to 1, the better the treatment.</p> <p>For example, if you give a stroke prevention drug to 20 people before 1 stroke is prevented, the number needed to treat is 20. See also number needed to harm, absolute risk reduction.</p>
Observational study	<p>Individuals or groups are observed or certain factors are measured. No attempt is made to affect the outcome. For example, an observational study of a disease or treatment would allow 'nature' or usual medical care to take its course. Changes or differences in one characteristic (for example, whether or not people received a specific treatment or intervention) are studied without intervening.</p> <p>There is a greater risk of selection bias than in experimental studies.</p>
Odds ratio	<p>Odds are a way to represent how likely it is that something will happen (the probability). An odds ratio compares the probability of something in one group with the probability of the same thing in another.</p> <p>An odds ratio of 1 between 2 groups would show that the probability of the event (for example a person developing a disease, or a treatment working) is the same for both. An odds ratio greater than 1 means the event is more likely in the first group. An odds ratio less than 1 means that the event is less likely in the first group.</p> <p>Sometimes probability can be compared across more than 2 groups – in this case, one of the groups is chosen as the 'reference category', and the odds ratio is calculated for each group compared with the reference category. For example, to compare the risk of dying from lung cancer for non-smokers, occasional smokers and regular smokers, non-smokers could be used as the reference category. Odds ratios would be worked out for occasional smokers compared with non-smokers and for regular smokers compared with non-smokers. See also confidence interval, risk ratio.</p>
Opportunity cost	<p>The loss of other healthcare programmes displaced by investment in or introduction of another intervention. This may be best measured by the health benefits that could have been achieved had the money been spent on the next best alternative healthcare intervention.</p>
Outcome	<p>The impact that a test, treatment, policy, programme or other intervention has on a person, group or population. Outcomes from interventions to improve the public's health could include changes in knowledge and behaviour related to health, societal changes (for example, a reduction in crime rates) and a change in people's health and wellbeing or health status. In clinical terms, outcomes could include the number of patients who fully recover from an illness or the number of hospital admissions, and an improvement or deterioration in someone's health, functional ability, symptoms or</p>

Term	Definition
	situation. Researchers should decide what outcomes to measure before a study begins.
P value	<p>The p value is a statistical measure that indicates whether or not an effect is statistically significant.</p> <p>For example, if a study comparing 2 treatments found that one seems more effective than the other, the p value is the probability of obtaining these results by chance. By convention, if the p value is below 0.05 (that is, there is less than a 5% probability that the results occurred by chance) it is considered that there probably is a real difference between treatments. If the p value is 0.001 or less (less than a 1% probability that the results occurred by chance), the result is seen as highly significant.</p> <p>If the p value shows that there is likely to be a difference between treatments, the confidence interval describes how big the difference in effect might be.</p>
Perioperative	The period from admission through surgery until discharge, encompassing the preoperative and postoperative periods.
Placebo	A fake (or dummy) treatment given to participants in the control group of a clinical trial. It is indistinguishable from the actual treatment (which is given to participants in the experimental group). The aim is to determine what effect the experimental treatment has had – over and above any placebo effect caused because someone has received (or thinks they have received) care or attention.
Polypharmacy	The use or prescription of multiple medications.
Posterior distribution	In Bayesian statistics this is the probability distribution for a statistic based after combining established information or belief (the prior) with new evidence (the likelihood).
Positive predictive value (PPV)	In screening or diagnostic tests: A measure of the usefulness of a screening or diagnostic test. It is the proportion of those with a positive test result who have the disease, and can be interpreted as the probability that a positive test result is correct. It is calculated as follows: $TP/(TP+FP)$
Postoperative	Pertaining to the period after patients leave the operating theatre, following surgery.
Post-test probability	In diagnostic tests: The proportion of patients with that particular test result who have the target disorder (post-test odds/[1 plus post-test odds]).
Power (statistical)	The ability to demonstrate an association when one exists. Power is related to sample size; the larger the sample size, the greater the power and the lower the risk that a possible association could be missed.
Preoperative	The period before surgery commences.
Pre-test probability	In diagnostic tests: The proportion of people with the target disorder in the population at risk at a specific time point or time interval. Prevalence may depend on how a disorder is diagnosed.
Prevalence	See Pre-test probability.
Prior distribution	In Bayesian statistics this is the probability distribution for a statistic based on previous evidence or belief.
Primary care	Healthcare delivered outside hospitals. It includes a range of services provided by GPs, nurses, health visitors, midwives and other healthcare professionals and allied health professionals such as dentists, pharmacists and opticians.
Primary outcome	The outcome of greatest importance, usually the one in a study that the power calculation is based on.

Term	Definition
Probabilistic analysis	In economic evaluation, this is an analysis that uses a probability distribution for each input. In contrast, see Deterministic analysis.
Product licence	An authorisation from the MHRA to market a medicinal product.
Prognosis	A probable course or outcome of a disease. Prognostic factors are patient or disease characteristics that influence the course. Good prognosis is associated with low rate of undesirable outcomes; poor prognosis is associated with a high rate of undesirable outcomes.
Prospective study	A research study in which the health or other characteristic of participants is monitored (or 'followed up') for a period of time, with events recorded as they happen. This contrasts with retrospective studies.
Publication bias	Publication bias occurs when researchers publish the results of studies showing that a treatment works well and don't publish those showing it did not have any effect. If this happens, analysis of the published results will not give an accurate idea of how well the treatment works. This type of bias can be assessed by a funnel plot.
Quality of life	See 'Health-related quality of life'.
Quality-adjusted life year (QALY)	A measure of the state of health of a person or group in which the benefits, in terms of length of life, are adjusted to reflect the quality of life. One QALY is equal to 1 year of life in perfect health. QALYS are calculated by estimating the years of life remaining for a patient following a particular treatment or intervention and weighting each year with a quality of life score (on a scale of 0 to 1). It is often measured in terms of the person's ability to perform the activities of daily life, freedom from pain and mental disturbance.
Randomisation	Assigning participants in a research study to different groups without taking any similarities or differences between them into account. For example, it could involve using a random numbers table or a computer-generated random sequence. It means that each individual (or each group in the case of cluster randomisation) has the same chance of receiving each intervention.
Randomised controlled trial (RCT)	A study in which a number of similar people are randomly assigned to 2 (or more) groups to test a specific drug or treatment. One group (the experimental group) receives the treatment being tested, the other (the comparison or control group) receives an alternative treatment, a dummy treatment (placebo) or no treatment at all. The groups are followed up to see how effective the experimental treatment was. Outcomes are measured at specific times and any difference in response between the groups is assessed statistically. This method is also used to reduce bias.
RCT	See 'Randomised controlled trial'.
Receiver operated characteristic (ROC) curve	A graphical method of assessing the accuracy of a diagnostic test. Sensitivity is plotted against 1 minus specificity. A perfect test will have a positive, vertical linear slope starting at the origin. A good test will be somewhere close to this ideal.
Reference standard	The test that is considered to be the best available method to establish the presence or absence of the outcome – this may not be the one that is routinely used in practice.
Reporting bias	See 'Publication bias'.
Resource implication	The likely impact in terms of finance, workforce or other NHS resources.
Retrospective study	A research study that focuses on the past and present. The study examines past exposure to suspected risk factors for the disease or condition. Unlike prospective studies, it does not cover events that occur after the study group is selected.

Term	Definition
Review question	In guideline development, this term refers to the questions about treatment and care that are formulated to guide the development of evidence-based recommendations.
Risk ratio (RR)	<p>The ratio of the risk of disease or death among those exposed to certain conditions compared with the risk for those who are not exposed to the same conditions (for example, the risk of people who smoke getting lung cancer compared with the risk for people who do not smoke).</p> <p>If both groups face the same level of risk, the risk ratio is 1. If the first group had a risk ratio of 2, subjects in that group would be twice as likely to have the event happen. A risk ratio of less than 1 means the outcome is less likely in the first group. The risk ratio is sometimes referred to as relative risk.</p>
Secondary outcome	An outcome used to evaluate additional effects of the intervention deemed a priori as being less important than the primary outcomes.
Selection bias	<p>Selection bias occurs if:</p> <p>a) The characteristics of the people selected for a study differ from the wider population from which they have been drawn, or</p> <p>b) There are differences between groups of participants in a study in terms of how likely they are to get better.</p>
Sensitivity	<p>How well a test detects the thing it is testing for.</p> <p>If a diagnostic test for a disease has high sensitivity, it is likely to pick up all cases of the disease in people who have it (that is, give a 'true positive' result). But if a test is too sensitive it will sometimes also give a positive result in people who don't have the disease (that is, give a 'false positive').</p> <p>For example, if a test were developed to detect if a woman is 6 months pregnant, a very sensitive test would detect everyone who was 6 months pregnant, but would probably also include those who are 5 and 7 months pregnant.</p> <p>If the same test were more specific (sometimes referred to as having higher specificity), it would detect only those who are 6 months pregnant, and someone who was 5 months pregnant would get a negative result (a 'true negative'). But it would probably also miss some people who were 6 months pregnant (that is, give a 'false negative').</p> <p>Breast screening is a 'real-life' example. The number of women who are recalled for a second breast screening test is relatively high because the test is very sensitive. If it were made more specific, people who don't have the disease would be less likely to be called back for a second test but more women who have the disease would be missed.</p>
Sensitivity analysis	<p>A means of representing uncertainty in the results of economic evaluations. Uncertainty may arise from missing data, imprecise estimates or methodological controversy. Sensitivity analysis also allows for exploring the generalisability of results to other settings. The analysis is repeated using different assumptions to examine the effect on the results.</p> <p>One-way simple sensitivity analysis (univariate analysis): each parameter is varied individually in order to isolate the consequences of each parameter on the results of the study.</p> <p>Multi-way simple sensitivity analysis (scenario analysis): 2 or more parameters are varied at the same time and the overall effect on the results is evaluated.</p> <p>Threshold sensitivity analysis: the critical value of parameters above or below which the conclusions of the study will change are identified.</p>

Term	Definition
	Probabilistic sensitivity analysis: probability distributions are assigned to the uncertain parameters and are incorporated into evaluation models based on decision analytical techniques (for example, Monte Carlo simulation).
Significance (statistical)	A result is deemed statistically significant if the probability of the result occurring by chance is less than 1 in 20 ($p < 0.05$).
Specificity	The proportion of true negatives that are correctly identified as such. For example in diagnostic testing the specificity is the proportion of non-cases correctly diagnosed as non-cases. See related term 'Sensitivity'. In terms of literature searching a highly specific search is generally narrow and aimed at picking up the key papers in a field and avoiding a wide range of papers.
Stakeholder	An organisation with an interest in a topic that NICE is developing a guideline or piece of public health guidance on. Organisations that register as stakeholders can comment on the draft scope and the draft guidance. Stakeholders may be: manufacturers of drugs or equipment national patient and carer organisations NHS organisations organisations representing healthcare professionals.
State transition model	See Markov model
Systematic review	A review in which evidence from scientific studies has been identified, appraised and synthesised in a methodical way according to predetermined criteria. It may include a meta-analysis.
Time horizon	The time span over which costs and health outcomes are considered in a decision analysis or economic evaluation.
Transition probability	In a state transition model (Markov model), this is the probability of moving from one health state to another over a specific period of time.
Treatment allocation	Assigning a participant to a particular arm of a trial.
Univariate	Analysis which separately explores each variable in a data set.
Utility	In health economics, a 'utility' is the measure of the preference or value that an individual or society places upon a particular health state. It is generally a number between 0 (representing death) and 1 (perfect health). The most widely used measure of benefit in cost–utility analysis is the quality-adjusted life year, but other measures include disability-adjusted life years (DALYs) and healthy year equivalents (HYEs).

References

1. GRADE Working Group. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group website. 2011. Available from: <http://www.gradeworkinggroup.org/> Last accessed: 12/01/18.
2. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. London. National Institute for Health and Care Excellence, 2014. Available from: <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview>
3. National Institute for Health and Clinical Excellence. Social value judgements: principles for the development of NICE guidance. London. National Institute for Health and Clinical Excellence, 2008. Available from: <https://www.nice.org.uk/media/default/about/what-we-do/research-and-development/social-value-judgements-principles-for-the-development-of-nice-guidance.pdf>
4. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal 2013. London. National Institute for Health and Clinical Excellence, 2013. Available from: <http://publications.nice.org.uk/pmg9>
5. Novielli N, Cooper NJ, Abrams KR, Sutton AJ. How is evidence on test performance synthesized for economic decision models of diagnostic tests? A systematic appraisal of Health Technology Assessments in the UK since 1997. *Value in Health*. 2010; 13(8):952-57
6. Organisation for Economic Co-operation and Development (OECD). Purchasing power parities (PPP). 2012. Available from: <http://www.oecd.org/sdd/prices-ppp/> Last accessed: 15th May 2018.
7. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. *Journal of Clinical Epidemiology*. 2005; 58(10):982-90
8. Review Manager (RevMan) [Computer program]. Version 5. Copenhagen. The Nordic Cochrane Centre, The Cochrane Collaboration, 2015. Available from: <http://tech.cochrane.org/Revman>
9. Van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. *Statistics in Medicine*. 2002; 21(4):589-624
10. Van Houwelingen HC, Zwinderman KH, Stijnen T. A bivariate approach to meta-analysis. *Statistics in Medicine*. 1993; 12(24):2273-84
11. WinBUGS [Computer programme] version 1.4. Cambridge. MRC Biostatistics Unit University of Cambridge, 2015. Available from: <http://www.mrc-bsu.cam.ac.uk/software/bugs/the-bugs-project-winbugs/>